<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83710</article-id><article-id pub-id-type="doi">10.7554/eLife.83710</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-295180"><name><surname>Silva</surname><given-names>Rui P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-295181"><name><surname>Huang</surname><given-names>Yimin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4348-5688</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-295182"><name><surname>Nguyen</surname><given-names>Annalee W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1268-7164</contrib-id><email>annalee@utexas.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295183"><name><surname>Hsieh</surname><given-names>Ching-Lin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-295184"><name><surname>Olaluwoye</surname><given-names>Oladimeji S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7888-0672</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295185"><name><surname>Kaoud</surname><given-names>Tamer S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1298-8725</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-297546"><name><surname>Wilen</surname><given-names>Rebecca E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295186"><name><surname>Qerqez</surname><given-names>Ahlam N</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295187"><name><surname>Park</surname><given-names>Jun-Gyu</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-295188"><name><surname>Khalil</surname><given-names>Ahmed M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295189"><name><surname>Azouz</surname><given-names>Laura R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295190"><name><surname>Le</surname><given-names>Kevin C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5098-7737</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295191"><name><surname>Bohanon</surname><given-names>Amanda L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3371-3416</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295192"><name><surname>DiVenere</surname><given-names>Andrea M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-295193"><name><surname>Liu</surname><given-names>Yutong</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295194"><name><surname>Lee</surname><given-names>Alison G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295195"><name><surname>Amengor</surname><given-names>Dzifa A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295196"><name><surname>Shoemaker</surname><given-names>Sophie R</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295197"><name><surname>Costello</surname><given-names>Shawn M</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-295198"><name><surname>Padlan</surname><given-names>Eduardo A</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-6446"><name><surname>Marqusee</surname><given-names>Susan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7648-2163</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-238236"><name><surname>Martinez-Sobrido</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-4311"><name><surname>Dalby</surname><given-names>Kevin N</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9272-5129</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-115582"><name><surname>D'Arcy</surname><given-names>Sheena</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5055-988X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-184987"><name><surname>McLellan</surname><given-names>Jason S</given-names></name><email>jmclellan@austin.utexas.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" id="author-170703"><name><surname>Maynard</surname><given-names>Jennifer A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0363-8486</contrib-id><email>maynard@che.utexas.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>Department of Molecular Biosciences, The University of Texas at Austin</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>Department of Chemical Engineering, The University of Texas at Austin</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/049emcs32</institution-id><institution>Department of Chemistry and Biochemistry, The University of Texas at Dallas</institution></institution-wrap><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>Division of Chemical Biology and Medicinal Chemistry, The University of Texas at Austin</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00wbskb04</institution-id><institution>Texas Biomedical Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">San Antonio</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05kzjxq56</institution-id><institution>Laboratory of Veterinary Zoonosis, College of Veterinary Medicine, Chonnam National University</institution></institution-wrap><addr-line><named-content content-type="city">Gwangju</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an7q238</institution-id><institution>Department of Molecular and Cell Biology, University of California, Berkeley</institution></institution-wrap><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an7q238</institution-id><institution>Biophysics Graduate Program, University of California, Berkeley</institution></institution-wrap><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Retired</institution><addr-line><named-content content-type="city">Kensington</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an7q238</institution-id><institution>Department of Chemistry, University of California, Berkeley</institution></institution-wrap><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00hj54h04</institution-id><institution>LaMontagne Center for Infectious Diseases, The University of Texas at Austin</institution></institution-wrap><addr-line><named-content content-type="city">Austin</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Goo</surname><given-names>Leslie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Sawyer</surname><given-names>Sara L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02ttsq026</institution-id><institution>University of Colorado Boulder</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83710</elocation-id><history><date date-type="received" iso-8601-date="2022-09-26"><day>26</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-04"><day>04</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-02-01"><day>01</day><month>02</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.01.31.428824"/></event></pub-history><permissions><copyright-statement>© 2023, Silva, Huang, Nguyen et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Silva, Huang, Nguyen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83710-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83710-figures-v3.pdf"/><abstract><p>To address the ongoing SARS-CoV-2 pandemic and prepare for future coronavirus outbreaks, understanding the protective potential of epitopes conserved across SARS-CoV-2 variants and coronavirus lineages is essential. We describe a highly conserved, conformational S2 domain epitope present only in the prefusion core of β-coronaviruses: SARS-CoV-2 S2 apex residues 980–1006 in the flexible hinge. Antibody RAY53 binds the native hinge in MERS-CoV and SARS-CoV-2 spikes on the surface of mammalian cells and mediates antibody-dependent cellular phagocytosis and cytotoxicity against SARS-CoV-2 spike in vitro. Hinge epitope mutations that ablate antibody binding compromise pseudovirus infectivity, but changes elsewhere that affect spike opening dynamics, including those found in Omicron BA.1, occlude the epitope and may evade pre-existing serum antibodies targeting the S2 core. This work defines a third class of S2 antibody while providing insights into the potency and limitations of S2 core epitope targeting.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>coronavirus</kwd><kwd>MERS-CoV</kwd><kwd>spike</kwd><kwd>SARS-CoV-2</kwd><kwd>S2 core</kwd><kwd>S2 hinge</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI127521</award-id><principal-award-recipient><name><surname>McLellan</surname><given-names>Jason S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM133751</award-id><principal-award-recipient><name><surname>Marqusee</surname><given-names>Susan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI122753</award-id><principal-award-recipient><name><surname>Maynard</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>INV-017592</award-id><principal-award-recipient><name><surname>McLellan</surname><given-names>Jason S</given-names></name><name><surname>Maynard</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000928</institution-id><institution>Welch Foundation</institution></institution-wrap></funding-source><award-id>F-1767</award-id><principal-award-recipient><name><surname>Maynard</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000928</institution-id><institution>Welch Foundation</institution></institution-wrap></funding-source><award-id>F-0003-19620604</award-id><principal-award-recipient><name><surname>McLellan</surname><given-names>Jason S</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000928</institution-id><institution>Welch Foundation</institution></institution-wrap></funding-source><award-id>F-1390</award-id><principal-award-recipient><name><surname>Dalby</surname><given-names>Kevin N</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000928</institution-id><institution>Welch Foundation</institution></institution-wrap></funding-source><award-id>AT-2059-20210327</award-id><principal-award-recipient><name><surname>D'Arcy</surname><given-names>Sheena</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>2027066</award-id><principal-award-recipient><name><surname>Maynard</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>graduate fellowship</award-id><principal-award-recipient><name><surname>DiVenere</surname><given-names>Andrea M</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014989</institution-id><institution>Chan Zuckerberg Initiative</institution></institution-wrap></funding-source><award-id>investigator</award-id><principal-award-recipient><name><surname>Marqusee</surname><given-names>Susan</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution>UT Austin Texas Biologics</institution></institution-wrap></funding-source><award-id>grant</award-id><principal-award-recipient><name><surname>McLellan</surname><given-names>Jason S</given-names></name><name><surname>Maynard</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution>UT System Proteomics Network</institution></institution-wrap></funding-source><award-id>support</award-id><principal-award-recipient><name><surname>D'Arcy</surname><given-names>Sheena</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A new class of antibody binding a highly conserved epitope on the spike S2 domain of MERS-CoV, SARS-CoV, and SARS-CoV-2 viruses is described.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The COVID-19 pandemic is the latest and largest of three deadly coronavirus outbreaks, including those caused by SARS-CoV in 2002 and MERS-CoV in 2012. Despite the successes of vaccines and antibody therapeutics that neutralize SARS-CoV-2 virus by disrupting interactions between the ACE2 receptor and the spike fusion protein, mutations accumulating primarily in the S1 domain have resulted in widespread evasion of antibodies elicited against early virus strains. This has culminated in the currently circulating Omicron subvariants with &gt;30 amino acid changes that resist neutralization by all monoclonal antibodies with Emergency Use Authorization (<xref ref-type="bibr" rid="bib58">VanBlargan et al., 2022</xref>; <xref ref-type="bibr" rid="bib30">Imai et al., 2023</xref>) and cause breakthrough infections in fully vaccinated individuals. Moreover, the seven coronaviruses known to infect humans are closely related to strains found in wildlife, foreshadowing future coronavirus outbreaks.</p><p>The continued emergence of SARS-CoV-2 variants of concern underscores the need to identify therapeutic strategies more resistant to antigenic drift. Immunization with the entire spike ectodomain induces potently neutralizing antibodies that block binding of the receptor binding domain (RBD) to the ACE2 receptor (<xref ref-type="bibr" rid="bib68">Yuan et al., 2020</xref>), indicating that the RBD is a protective and immunogenic, as well as variable, antigen. In contrast to the S1 domain comprising the RBD and N-terminal domains, the S2 domain is highly conserved, with 63–98% sequence similarity in pairwise comparisons across the seven human coronaviruses (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Early in the pandemic, S2-directed antibodies often dominated the immune repertoire in convalescent patients, indicating that at least some S2 epitopes are immunogenic (<xref ref-type="bibr" rid="bib59">Voss et al., 2021</xref>). Moreover, the functionally analogous domains in the fusion proteins from influenza virus, respiratory syncytial virus, and human immunodeficiency virus are targeted by protective antibodies (<xref ref-type="bibr" rid="bib31">Impagliazzo et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Corti et al., 2017</xref>), supporting the hypothesis that the spike S2 domain may also be an effective target.</p><p>Whereas antibodies binding the spike RBD have been rigorously classified based on epitope recognized (<xref ref-type="bibr" rid="bib2">Barnes et al., 2020</xref>) and this information used to support development of RBD mosaic vaccines (<xref ref-type="bibr" rid="bib11">Cohen et al., 2022</xref>), a complementary analysis of the S2 domain is in its infancy. Fewer than 5% of the ~7000 anti-SARS-CoV-2 spike monoclonal antibody sequences in the CoV-AbDab database bind S2 as of July 2022 (<xref ref-type="bibr" rid="bib49">Raybould et al., 2021</xref>). Moreover, just two classes of S2 binding antibodies have been described in the literature: those binding the fusion peptide and adjacent S2' cleavage site (<xref ref-type="bibr" rid="bib15">Dacon et al., 2022</xref>; <xref ref-type="bibr" rid="bib38">Low et al., 2022</xref>; <xref ref-type="bibr" rid="bib55">Sun et al., 2022</xref>) and those binding the S2 stem proximal to the viral membrane (<xref ref-type="bibr" rid="bib29">Hsieh et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Pinto et al., 2021</xref>; <xref ref-type="bibr" rid="bib51">Sauer et al., 2021</xref>; <xref ref-type="bibr" rid="bib71">Zhou et al., 2022</xref>). Here, we define a third class of S2 antibody that binds the highly conserved S2 hinge region, which converts from a bent hairpin to extended alpha helix during the pre-to-post-fusion spike conformational change. Evaluation of the S2 hinge epitope and the impact of spike dynamics on epitope accessibility will inform our understanding of the role of S2 domain epitopes in antibody recognition.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A MERS S2 mouse immune library yields antibody 3A3 that also binds SARS-CoV-2 spike</title><p>Balb/c mice were immunized with stabilized MERS-CoV S2 protein and boosted 4 weeks later, resulting in robust serum antibody titers against the immunogen detectable at &gt;1:10,000 dilution. The MERS-CoV S2 protein MERS SS.V1 spans residues 763–1291 of the MERS-CoV spike protein with a C-terminal T4 phage fibritin (foldon) domain that assembles into a prefusion trimer (<xref ref-type="bibr" rid="bib29">Hsieh et al., 2021</xref>). An immune antibody library with ~3.1 × 10<sup>8</sup> individual clones expressed as scFv-c-myc tag-pIII fusion proteins was generated and displayed on M13 bacteriophage. After 3–4 panning rounds, &gt;80 clones binding both MERS S2 and SARS-2 spike were characterized, with ~85% of clones binding the shared foldon domain by ELISA (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). One foldon binder, 3E11, was carried forward as a control antibody along with the most promising spike-binding clone identified by phage ELISA, 3A3.</p></sec><sec id="s2-2"><title>Antibody 3A3 binds the S2 core at the HR1/CH hairpin hinge</title><p>Antibody 3A3 binds a highly conserved, conformational epitope spanning residues 980–1006 of the SARS-2 spike, at the apex of the S2 domain, distal to the viral envelope (<xref ref-type="fig" rid="fig1">Figure 1a</xref>), as determined by a combination of hydrogen-deuterium exchange mass spectrometry (HDX) and low-resolution cryo-EM. This region spans the hairpin hinge, joining the heptad repeat 1 (HR1) and the central helices (CH), and is referred to hereafter as the hinge epitope. This region plays a critical role in the spike conformational changes required for fusion of the viral envelope and target cell membrane. In the intact spike homotrimer, the membrane-proximal, stalk-like S2 domain is capped by S1 whose N-terminal and receptor-binding domains (RBD) form a responsive surface allowing each RBD to extend to an ‘up’ position for receptor binding or tuck into a ‘down’ position for immune shielding of the receptor-binding site. After the RBDs engage a receptor in the up position and target cell proteases prime the spike, the S1 domain is released from S2, propelling the fusion peptide into the target cell or endosomal membrane. The hinge then extends to form an alpha helix that bridges the viral envelope and target cell membrane, initiating fusion and leaving the spike in the post-fusion state (<xref ref-type="bibr" rid="bib7">Cai et al., 2020</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The hinge epitope spans the HR1/CH helices at the S2 apex.</title><p>(<bold>a</bold>) Monomeric SARS-2 2P spike (PDBID: 6VSB chain B) colored according to the HDX difference in deuterium fractional uptake between SARS-2 HexaPro spike alone and with 3A3 IgG at 10<sup>2</sup> s exchange. Residues lacking coverage are indicated in black. The figure was prepared using DynamX per residue output without statistics and PyMOL. (<bold>b</bold>) Cryo-EM 2D class averages of the SARS-2 S2 subunit bound to the 3A3 Fab. (<bold>c</bold>) Cryo-EM 3D reconstruction of the S2–3A3 Fab complex showing each S2 protomer binding one 3A3 Fab molecule. The pink 3D volume was generated from a focused refinement of one S2 protomer and 3A3 Fab. (<bold>d</bold>) A structure of the S2 subunit and a predicted structure of the 3A3 Fab shown as ribbons and fit into the cryo-EM map. The 3A3 Fab light (LC, orange) and heavy (HC, red) chains sandwich the apex of the spike S2 hinge (cyan).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>HDX summary table for spike peptides.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83710-fig1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Sequence conservation is higher in the S2 domain than the S1 domain across coronaviruses that infect humans.</title><p>Percent sequence identity and similarity between the spike (<bold>a</bold> and <bold>c</bold>, respectively) S1 subunits and (<bold>b</bold> and <bold>d</bold>, respectively) S2 subunits of the seven coronaviruses known to infect humans were analyzed using <ext-link ext-link-type="uri" xlink:href="https://fastademo.bioch.virginia.edu/fasta_www2/fasta_www.cgi?rm=lplalign">LALIGN/PLALIGN</ext-link> local alignment. The default values of the gap penalties of open = –12 and gap = –2 were used for S2 alignments but reduced to open = –10 and gap = –1 to allow for variable domain lengths in S1. GenBank protein sequence identification numbers (protein_id) used in these alignments were: NP_073551.1 for 229E, AFD64754.1 for NL63, BBA20979.1 for OC43, BBA20986.1 for HKU1, YP_009047204.1 for MERS, AYV99817.1 for SARS-1–1, and YP_009724390.1 for SARS-2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Many cross-reactive scFv-phage target the foldon domain.</title><p>Most monoclonal phage tested by ELISA on SARS-2 spike or the unrelated RSV F foldon-coated plates had cross-reactive binding, indicating targeting of the shared foldon domain. After round 4 of panning, these data show 3A3 in black, a close relative of 3A3 (two amino acid changes) in green, two other unique antibodies in red and purple, and foldon binders with closely related CDRH3 sequences in blue.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig1-figsupp2-v3.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Peptides monitored through all timepoints of deuteration for SARS-2 HexaPro spike alone and with 3A3 IgG or Fab.</title><p>A total of 192 peptides were monitored, covering 56.3% of the SARS-2 HexaPro spike sequence and averaging 3.34 redundancy per amino acid. All peptides were manually checked. SARS-2 spike features are indicated on the sequence, including glycosylation sites. Glycosylation was not included in the peptide search, so no peptides are recovered surrounding these sites.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig1-figsupp3-v3.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Deuterium uptake of SARS-2 HexaPro spike alone suggests the trimer is maintained under HDX conditions.</title><p>(<bold>a</bold>) Trimeric (i and ii) and monomeric (iii) SARS-2 2P spike (PDB: 6VSB) colored according to fractional deuterium uptake of the SARS-2 HexaPro spike alone after 10<sup>3</sup> s of exchange. The figure was prepared using DynamX per residue output and PyMOL. Residues lacking coverage are indicated in black. Structural features are labeled, including the central trimer interface that shows relatively low deuterium incorporation. (<bold>b</bold>) Spectra from a spike peptide spanning residues 991–1001, within the 3A3 epitope. The spectra show the width of isotopic distributions in the deuterated samples suggestive of conformational heterogeneity.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig1-figsupp4-v3.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>HDX identified the apex of the S2 domain as the 3A3 epitope.</title><p>Volcano plots showing changes in deuterium uptake in SARS-2 HexaPro spike peptides upon addition of (<bold>a</bold>) 3A3 IgG or (<bold>b</bold>) Fab after 10<sup>2</sup> s exchange. Significance cutoffs are an average change in deuterium uptake greater than 0.2 Da and a p-value less than 10<sup>–2</sup> in a Welch’s <italic>t</italic>-test (hatched box). Black dots indicate peptides with a significant decrease in deuterium uptake and their residue boundaries are labeled. (<bold>c</bold>) Uptake plots for these peptides are shown. Traces are SARS-2 HexaPro spike alone (black), with 3A3 IgG (blue), and with 3A3 Fab (orange). Error bars are ± 2σ from three or four technical replicates and sometimes too small to be visible. The y-axis is 70% of max deuterium uptake assuming the N-terminal residue undergoes complete back-exchange. Data have not been corrected for back-exchange. (<bold>d</bold>) The difference in deuterium fractional uptake between SARS-2 HexaPro spike alone and with 3A3 Fab at 10<sup>2</sup> s exchange is projected onto monomeric SARS-2 2P spike (PDB: 6VSB chain B). Image was prepared using DynamX per residue output without statistics and PyMOL. Residues lacking coverage are indicated in black. Structural features are labeled, including the 2P mutations at residues 986 and 987 (shown as sticks).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig1-figsupp5-v3.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title>HDX identified the spike-binding paratope in 3A3 IgG.</title><p>Volcano plots showing changes in deuterium uptake in 3A3 IgG (<bold>a</bold>) heavy chain and (<bold>b</bold>) light chain upon addition of SARS-2 HexaPro spike after 10<sup>2</sup> s exchange. Significance cutoffs are an average change in deuterium uptake greater than 0.2 Da and a p-value less than 10<sup>–2</sup> in a Welch’s t-test (hatched box). Black dots indicate peptides with a significant decrease in deuterium uptake and their residue boundaries are labeled. (<bold>c</bold>) Uptake plots for these peptides are shown. Traces are 3A3 IgG alone (black) and with SARS-2 HexaPro spike (gray). Error bars are ± 2σ from three or four technical replicates and sometimes too small to be visible. The y-axis is 70% of max deuterium uptake assuming the N-terminal residue undergoes complete back-exchange. Data have not been corrected for back-exchange.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig1-figsupp6-v3.tif"/></fig></fig-group><p>For HDX epitope analysis, we measured deuterium uptake of the SARS-2 HexaPro (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2020</xref>) spike alone and when bound by the 3A3 IgG or 3A3 Fab (<xref ref-type="supplementary-material" rid="supp1 supp2">Supplementary files 1 and 2</xref>). We tracked 192 unmodified peptides (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>) through the deuteration time course (10<sup>1</sup>, 10<sup>2</sup>, 10<sup>3</sup>, and 10<sup>4</sup> s). Analysis of the raw deuterium uptake in the SARS-2 HexaPro spike alone is consistent with a trimer during exchange with relatively low deuterium uptake in the helix at the center of the trimer and high deuterium uptake in the HR1 helix at the trimer’s surface (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4a</xref>). Analysis of the isotopic distribution width of peptides from regions of spike reported to display bimodal spectra (<xref ref-type="bibr" rid="bib13">Costello et al., 2022</xref>) further suggests conformational heterogeneity consistent with the trimeric spike sampling an open conformation (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> and <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4b</xref>). Antibody epitopes were identified by examining the difference in deuterium uptake between SARS-2 HexaPro spike in the free and antibody-bound states (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). We defined a significant difference as greater than 0.2 Da with a p-value &lt;0.01 (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5a and b</xref>). The binding of 3A3 IgG caused a significant decrease in 12 peptides that redundantly span residues 980–1006 of the SARS-2 HexaPro spike (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5c</xref>). These peptides have reduced deuterium uptake with 3A3 IgG at several timepoints during the exchange reaction. A similar result was obtained with the 3A3 Fab (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5c and d</xref>).</p><p>Antibody paratopes were similarly identified by comparing deuterium uptake of 3A3 IgG alone to that with an excess of SARS-2 HexaPro spike. We monitored 169 peptides that redundantly cover 80% of the 3A3 IgG sequence. This analysis implicated CDRs L2 (residues 53–59) and H3 (residues 105–109) as forming the paratope that interacts with SARS-2 HexaPro spike (<xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref>). The spike epitope identified by HDX is consistent with low-resolution cryogenic electron microscopy (cryo-EM) of 3A3 Fab bound to stabilized SARS-2 S2, which shows Fabs bound to the apex of each S2 protomer in a 1:1 stoichiometry (<xref ref-type="fig" rid="fig1">Figure 1b–d</xref>). The open S2 conformation of spike resulted in particles with varying degrees of protomer opening that precluded sorting into 3D classes for high-affinity structural resolution.</p></sec><sec id="s2-3"><title>Access to the hinge epitope depends on spike domain dynamics</title><p>Mapping of the hinge epitope onto full-length spike structures shows that this region is fully occluded by the S1 domain in the closed (three RBDs down) state but becomes increasingly visible in structures with one, two, or three RBDs up and with ACE2 bound (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). In fact, RBDs in the down position make direct hydrogen bonds with the 3A3 epitope at residues 983–988 (<xref ref-type="bibr" rid="bib27">Hossen et al., 2022</xref>), thereby excluding other binding interactions. Consistent with this structural analysis, simultaneous binding of ACE2 and 3A3 to spike was demonstrated by BLI in which immobilized 3A3 captured SARS-2 HexaPro and then soluble ACE2. In a similar experiment, control mAb 2–4, whose epitope spans adjacent RBDs in the down state, bound SARS-2 HexaPro but could not then bind ACE2 (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). Additionally, 3A3 did not bind SARS-2 HexaPro spike locked into the closed conformation by engineered disulfide bonds (<xref ref-type="bibr" rid="bib26">Henderson et al., 2020</xref>), although this constrained spike was recognized by mAb 2–4 (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). As expected from the structural analysis, 3A3 binding does not block ACE2 binding to the spike RBDs. Moreover, the hinge epitope is only accessible when RBDs have freedom to convert to the up position.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The hinge epitope is accessible only in an RBD-up and S2-open spike conformation.</title><p>(<bold>a</bold>) Trimeric SARS-2 spike in various conformations colored according to difference in deuterium fractional uptake between SARS-2 HexaPro spike alone and with 3A3 IgG. The hinge epitope within S2 is colored dark blue in structures of wild-type SARS-2 spike in the (i) three RBDs down or closed conformation (PDB: 6XR8) and in structures of stabilized spike with (ii) one RBD up (PDB: 6VSB), (iii) two RBDs up (PDB: 7A93), or (iv) three RBDs up while bound to ACE2 (red) in top-view and (v) sideview (PDB: 7A98). Residues lacking coverage in the HDX experiment are indicated in gray. (<bold>b</bold>) Antibody 3A3 (bottom) or control mAb 2–4 (top) were coupled to anti-Fab BLI sensors and allowed to capture HexaPro or nothing (buffer, green line), then dipped into buffer (baseline), and finally dipped into ACE2-Fc (ACE2, red) or nothing (buffer, blue). (<bold>c</bold>) BLI binding of immobilized control mAb 2–4 (top) or antibody 3A3 (bottom) to 100 nM HexaPro (solid) or HexaPro locked into the ‘closed’ conformation (dashed). Vertical dashed lines indicate start of dissociation phase. (<bold>d</bold>) The network of hydrogen bonds formed by residues E1031 and R1039 across protomers deep in the S2 core is shown on intact HexaPro spike and in detail in a top view (PDB: 6XKL). (<bold>e</bold>) Antibody 3A3 was coupled to anti-Fc BLI sensors and allowed to bind HexaPro or E1031R HexaPro (E1031R) spike protein. All BLI data are representative of biological duplicates. Each experiment was repeated in technical duplicate except e, which was tested once at each concentration to allow all data to be collected simultaneously for direct comparison. (<bold>f</bold>) Model of the kinetic changes required for antibody binding to the hinge epitope, including conversion of the RBDs into the up position and some degree of opening of the S2 domain in addition to typical antibody association and dissociation kinetics (generated using PDB 6XV8 and 7A98).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>BLI sensorgram data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83710-fig2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>HexaPro E1031R variant exposes the hinge epitope.</title><p>The kinetics of interconversion between the closed-S2 and open-S2 states of HexaPro and HexaPro E1031R were evaluated by HDX as previously described (<xref ref-type="bibr" rid="bib13">Costello et al., 2022</xref>). The spike proteins were incubated at 37°C for 24 hr, then incubated at 4°C, assayed for detecting the S2-open state over time, then transferred to 37°C and assayed again. The fraction closed-S2 was estimated by exposing a sample of the incubation reaction to a 1 min pulse of deuterium and quenching the labeling reaction with low pH and temperature. After LC-MS and peptide identification, the bimodal mass envelopes for all timepoints for one peptide were globally fit to a sum of two Gaussians, keeping the center and width of each Gaussian constant across all incubation time points. After fitting, the area under the lower molecular weight Gaussian was integrated to determine the fraction of closed-S2. For HexaPro, the half-life of conversion from closed to open (37°C → 4°C) was 143.5 hr and the half-life of conversion from open to closed (4°C → 37°C) was 2.5 hr. These conversions for HexaPro E1031R occur with half-lives decreased by &gt;700-fold (0.2 hr) and &gt;6-fold (0.4 hr), respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig2-figsupp1-v3.tif"/></fig></fig-group><p>Access to S2 core epitopes is only partially understood, as are the dynamics of spike breathing and other complex intra-protein spike motions. <xref ref-type="bibr" rid="bib13">Costello et al., 2022</xref> showed that stabilized spike undergoes reversible protomer opening in solution to expose the S2 core and the hinge epitope. They performed an independent HDX experiment under conditions favoring the open trimer conformation to show that 3A3 exclusively binds and stabilizes an S2-open state, distinct from the open/closed states used to describe RBD motion. Consistent with this report, 3A3 has a faster on-rate for spike variants favoring S2 opening versus unmodified spike. SARS-2 HexaPro bearing an E1031R substitution, which disrupts an electrostatic interaction between E1031 and R1039 on adjacent protomers deep in the S2 base (<xref ref-type="fig" rid="fig2">Figure 2d</xref>), favored the S2-open state relative to unmodified HexaPro as assessed by HDX (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and exhibited a fourfold increased on-rate for 3A3 binding (2.9 ± 0.1 µM<sup>–1</sup> s<sup>–1</sup>) versus unmodified HexaPro spike (0.8 ± 0.1 µM<sup>–1</sup> s<sup>–1</sup>; <xref ref-type="fig" rid="fig2">Figure 2e</xref>). This indicates that 3A3 binding to full-length spike occurs after the RBDs have transitioned to the up position and the S2 domain has relaxed into a more open state. Overall 3A3 binding rates thus depend on these transition rates in addition to typical antibody-antigen association and dissociation rates (<xref ref-type="fig" rid="fig2">Figure 2f</xref>).</p></sec><sec id="s2-4"><title>Antibody 3A3 binds a conformational epitope spanning the 2P stabilizing mutations</title><p>To validate the HDX and cryo-EM data and define the 3A3 epitope with single amino acid resolution, 16 solvent-exposed epitope residues were individually altered in HexaPro to assess the impact on 3A3 binding. Three changes (L984A, Q992L, and R995A) improved 3A3 binding, while five (D985L, E988Q or I, D994A, and L1001A) significantly reduced 3A3 binding by ELISA (<xref ref-type="fig" rid="fig3">Figure 3a</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Substitutions nearly ablated binding at positions D985 and E988, which form a negatively charged patch adjacent to the stabilizing 2P changes, P986 and P987 (<xref ref-type="fig" rid="fig3">Figure 3b and c</xref>). Since E988Q is present in the spike proteins of α-coronaviruses NL63 and 229E, this suggests 3A3 binding may be limited to β-coronavirus spike proteins. When SARS-2 D614G lentivirus containing D985L, E988A, or E988Q substitutions were evaluated for the ability to infect ACE2-expressing HEK 293 cells, all had impaired infectivity (55–98% reduction at the highest titer tested; <xref ref-type="fig" rid="fig3">Figure 3d</xref>), suggesting that escape mutations within this epitope have a high fitness cost. Indeed, GISAID genomic sequence data analyzed by Los Alamos National Laboratory’s COVID-19 Viral Genome Analysis Pipeline (<xref ref-type="bibr" rid="bib33">Korber et al., 2020</xref>) accessed in August 2022 showed that the Shannon entropy of positions 985 and 988 was &gt;40-fold and &gt;150-fold reduced relative to the average Shannon entropy of the SARS-2 S2 domain and full SARS-2 spike ectodomain, respectively. Pseudotyped virions bearing spike with 988Q found in α-coronaviruses were least impacted, consistent with tolerance to this substitution for spike function. Importantly, single mutations within this epitope that have emerged, L981F in SARS-2 Omicron BA.1 spike (which reverted in subsequent Omicron variants BA.2 through BA.5) and S982A in SARS-2 Alpha spike, had no significant impact on 3A3 binding (<xref ref-type="fig" rid="fig3">Figure 3a</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>SARS-2 spike residues 985–988 are recognized by 3A3 and impair spike function upon substitution.</title><p>(<bold>a</bold>) Residues important for 3A3 binding were identified by single residue changes in HexaPro that increased or decreased binding to 3A3 relative to HexaPro. Each variant was tested with duplicate technical replicates in 2–6 independent ELISA assays. Significance relative to unaltered HexaPro was determined by ANOVA with post-hoc Tukey–Kramer test with <italic>α</italic> = 0.01; data meeting this criterion indicated by *. (<bold>b</bold>) Location of the residue changes altering binding to 3A3 shown in the HexaPro spike (6XKL) monomer and in (<bold>c</bold>) intact spike (side view) and the S2 domain (top-down view). All epitope residues (980–1006) are shown in space-fill, with residues colored according to their effect on 3A3 binding: improved binding (orange), reduced binding (teal), no effect (black), and those not altered (gray). The 2P stabilizing mutations within the hinge epitope are displayed in purple. (<bold>d</bold>) The infectivity of lentivirus pseudotyped with unmodified D614G SARS-2 spike or variants with D985L (green), E988A (light blue), and E988Q (dark blue) substitutions was compared by luciferase activity. Data shown are the mean luminescence with standard deviation of three technical replicates.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>ELISA binding data and relative luminescence data for pseudovirus infection assays.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83710-fig3-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>HexaPro variants with reduced 3A3 binding retain trimer SEC profile.</title><p>The single-point mutants of HexaPro, D985L, E988I, D994A, and L1001A, had reduced binding to 3A3 relative to HexaPro (<xref ref-type="fig" rid="fig3">Figure 3a</xref>), but retained the overall size of unmodified HexaPro by SEC with elution of the main peak at ~13.75 mL on a Superose 6 Increase 30/100 column, indicating the spike was intact. Molecular weight markers (black triangles) on the x-axis are peak elution volumes from the following standards in order from left to right: thyroglobulin (669 kDa, 13.49 mL), ferritin (440 kDa, 15.40 mL), β-amylase (200 kDa, 16.75 mL), and aldolase (158 kDa, 17.91 mL).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig3-figsupp1-v3.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>The hinge epitope is nonlinear and inaccessible in aggregated or misfolded protein.</title><p>(<bold>a</bold>) 3E11 binds reduced, denatured SARS-2 HP, SARS-2, and MERS spike proteins by Western blot, but 3A3 does not. The ladder molecular weight is labeled in kDa on the left side. (<bold>b</bold>) SDS-PAGE analysis of fresh and stressed SARS-2 and SARS-2 HexaPro spikes shows a substantial aggregation of the stressed SARS-2 spike. For each spike, 8 μg of protein was analyzed by SDS-PAGE under nonreducing conditions. Reduced band intensity of stressed SARS-2 spike (bottom arrow) and appearance of a band just under the loading wells (top arrow) indicates aggregation products not apparent in the other samples. Densitometry analysis (ImageJ) of these bands indicates that the stressed SARS-2 spike’s main peak is diminished by ~20% relative to the fresh SARS-2 spike intensity. Ladder molecular weights in kDa are indicated to the left of the gel image. Binding of 3A3 Fab to HexaPro S2 measured (<bold>c</bold>) ELISA capture of fresh (red circles) or stressed (pink diamonds) SARS-2 spike on 3A3 coated plates. (<bold>d</bold>) Antibodies coated on ELISA plates captured fresh (dark blue or red) or stressed (pink or light blue) SARS-2 HP (blue) or SARS-2 (red) spike proteins. Duplicate dilutions of spike over ~5 log in concentration were used to calculate EC<sub>50</sub> values. For dilution series in which no binding was observed, EC<sub>50</sub> was assumed to be &gt;1000 nM. Open symbols are replicate data and filled rectangles are average data.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig3-figsupp2-v3.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Original blot images for <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a</xref>.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig3-figsupp3-v3.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Adding a disulfide bond slightly improves 3A3 binding by ELISA to spike with P986 and P987 reverted to the native sequence.</title><p>Antibody 3A3 was coated on high binding plates and allowed to bind dilutions of SARS-2 HexaPro spike, 4P spike (HexaPro with P986K and P987V reversions), or 4P-DS spike (4P with an additional stabilizing disulfide). For detection, streptactin-HRP was allowed to bind the twin strep tag sequence at the C-terminus of any captured spike proteins.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig3-figsupp4-v3.tif"/></fig></fig-group><p>Antibody 3A3 could not detect fully denatured coronavirus spike in Western blot (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>), consistent with recognition of the folded, bent S2 hinge conformation. After three freeze/thaw cycles, aggregates were detectable by SDS-PAGE in the SARS-2 spike but not in the stress-resistant (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2020</xref>) SARS-2 HexaPro. (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b</xref>). The control foldon-binding antibody 3E11 bound fresh and stressed proteins similarly, but 3A3 binding to stressed 2P spike was greatly decreased (~150-fold worse ELISA EC<sub>50</sub>), while binding of stressed SARS-2 HexaPro was unaffected (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2c and d</xref>). These data are consistent with the HDX and cryo-EM data indicating that 3A3 binds properly folded, pre-fusion spike.</p><p>Residues K986 and V987 are substituted with prolines in the stabilized SARS-2 2P and HexaPro soluble spikes used by most laboratories as these changes substantially improve the yield and stability of soluble prefusion spike. Given their proximity to hot spot residues D985 and E988 within the hinge epitope, we reverted 2P to the native sequence and evaluated the impact on 3A3 binding (<xref ref-type="fig" rid="fig3">Figure 3a–c</xref>). Binding to this 4P spike (HexaPro with P986K and P987V) was dramatically impaired. Since proline side chains are part of the main chain backbone, the 2P changes may serve to rigidify the epitope and/or the native lysine residue may introduce steric or electrostatic clashes. To mimic the prefusion bent conformation without 2P, we introduced a disulfide bond between amino acids 965 and 1003 (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2020</xref>) in 4P to create 4P-DS. By ELISA, 3A3 binding to 4P-DS was partially recovered (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). Collectively, these data demonstrate that antibody 3A3 binds a conformational hinge epitope dominated by residues D985 and E988 and rigidified by the adjacent stabilizing 2P changes.</p></sec><sec id="s2-5"><title>Antibody RAY53 binds the authentic SARS-2 spike hinge epitope</title><p>To understand the role of the hinge epitope in the context of authentic spike, we expected that an engineered version of 3A3 would be necessary to accommodate 986K and thereby improve binding to 4P, 4P-DS, and authentic spike. We evaluated several humanized 3A3 variants as previously described (<xref ref-type="bibr" rid="bib41">Nguyen et al., 2015</xref>), yielding hu3A3 which bound HexaPro similarly to 3A3 by ELISA (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). To identify variants binding 4P-DS more strongly, two hu3A3 Fab libraries of ~3 × 10<sup>7</sup> members each were generated in a yeast display plasmid: a random mutagenesis library (<xref ref-type="bibr" rid="bib21">Fromant et al., 1995</xref>) with an error rate of 0.3% and a site-directed mutagenesis library targeting three residues in CDRL2 and five residues in CDRH3 implicated in spike recognition by HDX. After 3–4 rounds of sorting for enhanced 4P-DS binding (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), individual clones were isolated. Combinatorial expression of selected V<sub>H</sub> and V<sub>L</sub> regions as IgG1 antibodies followed by ELISA screening for 4P-DS binding identified RAY53, comprised of a light chain from the site-directed library and a heavy chain from the random mutagenesis library.</p><p>RAY53 shows greatly improved binding to 4P-DS spike versus 3A3 (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3a and b</xref>) while retaining 3A3’s epitope sensitivity (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c</xref>). Fab 3A3 binds stabilized SARS-2 HexaPro S2 with ~3 nM equilibrium K<sub>d</sub>, as measured by BLI and SPR (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4a and b</xref>); RAY53 binds SARS-2 HexaPro similarly (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4f</xref>). However, while 3A3 IgG1 binding to 4P-DS and 4P spikes was too weak for quantitation at the concentrations used (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>), SPR analysis of RAY53 IgG1 binding to 4P-DS indicated a K<sub>d</sub> of 100 ± 16 nM (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4c</xref>). Interestingly, the RAY53 Fab K<sub>d</sub> was 1.3 ± 0.2 µM, ~13-fold lower than the corresponding IgG (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4d</xref>), suggesting both IgG arms simultaneously engage protomers within the same spike in this SPR orientation, consistent with cryo-EM images (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). Overall, RAY53 retained binding to stabilized HexaPro spike while accommodating the native K986/V987 hinge residues.</p></sec><sec id="s2-6"><title>The hinge epitope is highly conserved across β-coronaviruses but susceptible to structural occlusion</title><p>The spike hinge at SARS-2 amino acids 980–1006 exhibits high sequence and structural conservation across all β-coronaviruses known to infect humans (<xref ref-type="fig" rid="fig4">Figure 4a and b</xref>), with Cα atom RMSDs ranging from 0.6 Å for HKU1 to 3.1 Å for MERS. To assess the phylogenetic range of spikes recognized by 3A3 and RAY53, binding to diverse coronavirus spikes was assessed by ELISA (<xref ref-type="fig" rid="fig4">Figure 4c</xref>). Antibodies 3A3 and RAY53 bound each of the 2P stabilized spikes similarly, with improved RAY53 binding observed for SARS-2 4P, 4P-DS, and HKU1. Binding of 3A3 to proline-stabilized SARS-2 HexaPro, SARS-2, aglycosylated SARS-2 HexaPro, SARS-1 and MERS spike was apparent with BLI-measured on-rates of ~0.2–1.3 µM<sup>–1</sup> s<sup>–1</sup>; equivalent association rates were observed for RAY53 binding to the stabilized spikes tested (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4f</xref>). Although both 3A3 and RAY53 bound SARS-2 HexaPro Omicron BA.1 by BLI, the on-rate was reduced ~15-fold relative to HexaPro. Binding of RAY53 was maintained for diverse β-coronavirus spike proteins, consistent with the high sequence identity of this epitope.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The hinge epitope is conserved across β-coronaviruses and variably accessible in authentic spike.</title><p>The hinge epitope recognized by 3A3 (SARS-2 amino acids 980–1006) is highly conserved across the spike (<bold>a</bold>) sequences and (<bold>b</bold>) structures of β-coronaviruses known to infect humans, including Alpha, Omicron BA.1, and other variants of concern (VOC; Beta, Gamma, Delta, Epsilon, Omicron BA.2 through BA.5). In (<bold>a</bold>), identical residues are indicated by a dot and similar residues are highlighted in gray. Residues conserved across all listed β-coronaviruses are in bold. Residues that lost binding to 3A3 when altered as shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> are in teal highlight and those whose disruption improved binding are orange. The location of the two proline mutations introduced to 2P variants are shown below the alignment. In (<bold>b</bold>), the structure of each epitope is displayed as follows: SARS-2 (6VSB) – red, SARS-1 (6CRV, RMSD = 0.8 Å) – magenta, MERS (5X5C, RMSD = 3.1 Å) – blue, HKU1 (5I08, RMSD = 0.5 Å) – teal, OC43 (6OHW, RMSD = 0.6 Å) – green. (<bold>c</bold>) Binding of full-length antibody 3A3 (black circles) and RAY53 (blue diamonds) to ancestral SARS-2, SARS-2 HexaPro (SARS-2 HP), SARS-2 4P, SARS-2 4P-DS, SARS-2 HexaPro Delta (SARS-2 HP Delta), SARS-2 HexaPro Omicron BA.1 (SARS-2 HP Omicron BA.1), MERS, SARS-1, HKU1, or milk (no coat) proteins by ELISA. Data are representative of duplicate biological replicates, each with duplicate technical replicates. The data midpoint is indicated with a bar. (<bold>d</bold>) Plasmids encoding full-length unstabilized spike proteins from SARS-2, SARS-2 Omicron BA.1, MERS, or SARS-1 were transiently transfected to Expi293 cells. The spike (blue or magenta histograms) or mock (grey histograms) transfected cells were stained with 100 nM RAY53 (top panels) or 10 nM control antibody S309 (bottom panels), followed by goat-anti-human Fc-PE secondary antibody, and flow cytometry scanning of 10,000 cells. The data shown are representative of triplicate experiments, with each condition repeated in technical duplicate. (<bold>e</bold>) Expi293 cells were transiently transfected with plasmids encoding SARS-2 spike and EGFP or EGFP only, then incubated with 3A3 (black circles) or RAY53 (blue diamonds) antibody (~1–300 nM) and anti-human Fc-PE before flow cytometric determination of the geometric mean fluorescence intensity (GMFI) in the PE channel for all green fluorescent cells. The GMFI of cells transfected with EGFP only was subtracted from the GMFI of cells expressing spike at each concentration, and the data fit to a three-parameter logistic curve to determine the effective K<sub>d</sub> (K<sub>d,eff</sub>) for antibody binding. The data shown are representative of triplicate experiments; ND, not detected.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>ELISA data and flow cytometry mean fluorescence intensity data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83710-fig4-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Antibody hu3A3 binds SARS-2 HexaPro similarly to 3A3 by ELISA.</title><p>SARS-2 HexaPro spike was coated on high binding plates and allowed to bind dilutions of 3A3 or hu3A3 purified antibody, then anti-human Fc-HRP for detection.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Antibody hu3A3 yeast display libraries were enriched for binding to 4P-DS.</title><p>Yeast surface display of irrelevant Fab or the hu3A3 Fab resulted in minimal binding to AF647 conjugated 4P-DS spike by flow cytometry. Site-directed (SD) or error-prone (EP) strategies to introduce diversity into the variable regions of hu3A3 Fab resulted in two libraries shown unsorted (R0), and after one (R1), two (R2), three (R3), or four (R4) rounds of selection. The 4P-DS-binding population was enriched by &gt;70-fold during sorting of each library.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig4-figsupp2-v3.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Antibody RAY53 retains epitope specificity while exhibiting higher affinity than 3A3 for SARS-2 HexaPro spike with reverted 2P changes.</title><p>(<bold>a</bold>) ELISA data with spike 4P-DS or 4P coated on high binding plates, followed by the addition antibody 3A3 or RAY53 in a 1:5 dilution series and detection with anti-human Fc-HRP secondary antibody. (<bold>b</bold>) Raw SPR curves showing binding of immobilized 4P-DS to 3A3 or RAY53 as full-length human IgG1 at 500 nM or human Fab at 1000 nM. These curves are representative of duplicate data. (<bold>c</bold>) The same substitutions used for fine epitope mapping of 3A3 were analyzed for ELISA binding to RAY53 as described in <xref ref-type="fig" rid="fig3">Figure 3a</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig4-figsupp3-v3.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Antibodies 3A3 and RAY53 have low-to-mid nanomolar affinities for stabilized SARS-2 spike variants.</title><p>Binding of 3A3 Fab to HexaPro S2 was measured by (<bold>a</bold>) BLI with the HexaPro S2 trimer immobilized on the biosensor and (<bold>b</bold>) SPR with Fab immobilized on the chip. SPR was also used to evaluate binding of SARS-2 4P-DS to immobilized (<bold>c</bold>) IgG RAY53, (<bold>d</bold>) Fab RAY53 or (<bold>e</bold>) control IgG22. For BLI, K<sub>d</sub> values were obtained using a 1:1 global fit model using the Octet instrument software. The SPR data were double-reference subtracted and fit to a 1:1 binding model using BIAevaluation software. (<bold>f</bold>) Binding of 3A3 and RAY53 IgG to additional spike variants was compared by incubating full-length IgGs immobilized on anti-Fc BLI sensors with serially diluted spike variants for an association step followed by a dissociation step in buffer only. Since the off-rates determined for this 3:1 spike protomer:antibody binding arm format using kinetic-based K<sub>d</sub> were extremely slow due to rebinding (~10<sup>–12</sup> s<sup>–1</sup>) and differential epitope accessibility is expected to influence the observed on-rate (<xref ref-type="fig" rid="fig2">Figure 2f</xref>), on-rates (<italic>k</italic><sub>on</sub>) were compared. Vertical lines indicate the start of the dissociation phase; data shown in solid lines with fits (1:1 association then dissociation fit using GraphPad Prism software) shown in red lines.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig4-figsupp4-v3.tif"/></fig></fig-group><p>To evaluate the binding of RAY53 to a range of unmodified β-coronavirus spikes, authentic SARS-2 (wild-type and Omicron BA.1), MERS, and SARS-1 spikes were displayed on the surface of Expi293 cells and stained with antibody (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). The soluble expression of authentic coronavirus spike without stabilizing mutations results in poor yield and misfolded proteins, preventing accurate measurement of binding affinities. Moreover, measurement of an ‘effective’ affinity based on binding to many spike proteins on the mammalian cell surface (<xref ref-type="bibr" rid="bib20">Feldhaus and Siegel, 2004</xref>) is more indicative of antibody interactions with authentic spike during infection. Excluding the non-binding population consequent to transient expression, control antibody S309 bound SARS-2 and SARS-1 spike-expressing cells but not MERS spike-expressing cells, as expected (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). Binding of RAY53 to wild-type SARS-2 spike yielded an effective K<sub>d</sub> of 100 ± 20 nM, nearly identical to the 100 nM affinity measured by SPR for 4P-DS (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4c</xref>), with no 3A3 binding above background detected (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). Overall, we conclude that affinity maturation to 4P-DS improved RAY53 binding to the hinge epitope found in authentic spike.</p><p>Interestingly, RAY53 bound SARS-2 and MERS spikes, but not SARS-2 Omicron BA.1 or SARS-1 spikes. The contrast between high RAY53 binding to stabilized SARS-2 HexaPro Omicron BA.1 (<xref ref-type="fig" rid="fig4">Figure 4c</xref>) and dramatic loss of binding to cell-surface displayed Omicron BA.1 implicates structural differences between the two spike formats as opposed to the single epitope mutation which is inert on its own (L981F, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c</xref>). SARS-2 Omicron BA.1 spike has accumulated mutations that result in tight packing of the RBDs in the down state, occluding many neutralizing RBD epitopes and aiding in immune evasion (<xref ref-type="bibr" rid="bib22">Gobeil et al., 2022</xref>). We expect this tightly packed RBD surface will also impede access to the S2 core, including the hinge epitope. Similarly, strong RAY53 binding to stabilized SARS-1 spike was completely lost when spike was expressed without stabilizing mutations on the cell surface, despite an unaltered hinge epitope (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). Overall, these data suggest mutations distal to the hinge epitope can restrict antibody access and this effect is lost in proline-stabilized spike.</p></sec><sec id="s2-7"><title>Targeting the hinge epitope inhibits cellular fusion and neutralizes pseudovirus but not authentic virus infection and mediates Fc effector functions</title><p>To investigate the impact of antibody binding on hinge function, we first employed a mammalian cell fusion assay (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). A CHO cell line expressing wild-type SARS-2 spike and EGFP was incubated with ACE2-expressing HEK 293 cells stained with red fluorescent Cell Trace Far Red. After 24 hr, large syncytia formed with green CHO cell fluorescence overlapping ~70% of red HEK 293 cell fluorescence, indicating fusion of the CHO and HEK 293 membranes in the presence of no antibody or 670 nM irrelevant human IgG1. Incubation with 670 nM or 67 nM of 3A3 significantly reduced colocalization to ~50% (p&lt;0.0001) and significantly reduced syncytia size was noted down to 6.7 nM. These data indicate that 3A3 can prevent spike’s ability to fuse viral and cell membranes.</p><p>We next compared 3A3 and RAY53 in an in vitro pseudovirus neutralization assay to determine whether stronger epitope binding improved neutralization. These antibodies, the potently neutralizing antibody S309 (<xref ref-type="bibr" rid="bib46">Pinto et al., 2020</xref>), or an isotype control antibody were incubated with lentivirus expressing authentic spikes and added to HEK293 cells expressing the relevant receptor with infection monitored by luciferase expression (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). Control antibody S309 potently neutralized SARS-1 and SARS-2 spike lentivirus (IC<sub>50</sub> of ~0.5 nM), similar to MLV pseudovirus reports (<xref ref-type="bibr" rid="bib46">Pinto et al., 2020</xref>), but was approximately tenfold less potent against SARS-2 Omicron BA.1 and ineffective against MERS pseudoviruses, as expected (<xref ref-type="bibr" rid="bib8">Cameroni et al., 2022</xref>). By contrast, 3A3 and RAY53 weakly and incompletely blocked infection of wild-type SARS-2 and MERS pseudoviruses (estimated IC<sub>50</sub> values &gt;50 nM) but did not block infection by SARS-1 or SARS-2 Omicron BA.1 pseudoviruses. Incomplete pseudovirus neutralization has been noted in other studies, particularly with antibodies that do not directly block ACE2 binding, although it is unclear why this occurs (<xref ref-type="bibr" rid="bib50">Rogers et al., 2020</xref>). Despite greatly improved binding to 4P-DS (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3a and b</xref>) and authentic SARS-2 spike on the mammalian cell surface (<xref ref-type="fig" rid="fig4">Figure 4e</xref>), RAY53 did not neutralize pseudovirus better than 3A3, indicating that antibody binding is not the rate-limiting step in neutralizing the hinge epitope (<xref ref-type="fig" rid="fig2">Figure 2f</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Targeting the hinge epitope recruits Fc effector functions.</title><p>(<bold>a</bold>) Neutralization was evaluated by pre-incubating antibody with pseudotyped HIV particles that were then added to HEK 293T cells stably expressing ACE2 (SARS-1 and SARS-2 pseudoviruses) or DPP4 (MERS pseudovirus), with viral entry detected by luciferase luminescence. The entry efficiency of pseudoviruses without any treatment was considered 100%. (<bold>b</bold>) Neutralization of authentic SARS-2 wild-type virus was assessed by incubating viral particles with antibody before adding to Vero HF cells. Viral infection was assessed by ELISPOT 24 hr after infection by immunostaining with the anti-SARS-2 nucleocapsid antibody 1C7C7. (<bold>c</bold>) ADCP was performed by co-incubating undifferentiated THP-1 cells, antibodies and pHrodo-Green/APC-polystyrene beads coated with HexaPro or 4P-DS. The phagocytosis score was calculated as the percent of positive APC/FITC cells multiplied by the GMFI for APC. Data were collected from two separate experiments with the average and standard deviation shown. (<bold>d</bold>) ADCC was assessed by incubating NK-92 V/V cells, HEK-293T cells transfected to express either wild-type SARS-2 spike (spike) or nothing (mock) and antibody. For each panel, data shown are representative of three biological replicates. Duplicate technical replicates with the midpoint of each condition are shown.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Data reporting antibody effect on infection with pseudovirus, authentic virus, phagocytosis score, and cellular lysis.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83710-fig5-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Antibody 3A3 inhibits cellular fusion induced by the interaction of SARS-2 spike with human ACE2.</title><p>(<bold>a</bold>) HEK 293 cells stably expressing human ACE2 were stained with Cell Trace Far Red and incubated with a CHO-based cell line transiently expressing authentic SARS-2 spike and EGFP. The cultures were imaged after 24 hr of incubation for EGFP (green) or Cell Trace Far Red (red) and the level of colocalization (yellow) was evaluated. (<bold>b</bold>) CHO cells not expressing SARS-2 spike and (<bold>c</bold>) HEK 293 cells not expressing ACE2 exhibited minimal fusion. (<bold>d</bold>) When the cultures were preincubated with an irrelevant isotype control antibody, extensive fusion and syncytia formation equivalent to no antibody was apparent. Incubation at (<bold>e</bold>) 6.7, (<bold>f</bold>) 67, and (<bold>g</bold>) 670 nM 3A3 reduced fusion in a dose-dependent manner with significance reached at 67 nM. Scale bar, 100 μm. (<bold>h</bold>) The percentage of HEK-ACE2 pixels (red) colocalizing with spike expressing CHO pixels (green) was analyzed with the JACoP plugin for ImageJ. (<bold>i</bold>) The same images were analyzed for the average cell size of fused HEK-ACE2 with ImageJ as a second statistical method to test the cell fusion level. Shown are the mean and standard deviation of at least 160 cells per condition from 8 to 9 independent images. The statistical analysis of average cell sizes under different conditions were performed with ANOVA followed by Tukey’s HSD test. Results shown are representative of four independent experiments; ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83710-fig5-figsupp1-v3.tif"/></fig></fig-group><p>With the understanding that these considerations may be different still in a live coronavirus context, neutralization of authentic SARS-2 wild-type virus by 3A3 and RAY53 alongside an isotype control and S309 positive control was tested in vitro (<xref ref-type="fig" rid="fig5">Figure 5b</xref>). In contrast to pseudotyped lentivirus, neither 3A3 nor RAY53 exhibited neutralization of the authentic virus in this assay. This difference may be caused by several factors, including the specific neutralization protocol used or variation in spike structure and/or dynamics in the specific environment of the virion surface.</p><p>In addition to neutralization, antibodies binding spike can mediate Fc effector functions and thereby eliminate viral particles and infected cells. When SARS-2 HexaPro spike was coated on beads and incubated with S309, 3A3, or RAY53, the beads were effectively internalized by human THP-1 monocytes in an in vitro ADCP assay (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). When 4P-DS was used, only S309 and RAY53 but not 3A3 or an isotype control mediated ADCP, consistent with RAY53’s higher affinity to the exposed hinge epitope on 4P-DS. In an in vitro ADCC assay, HEK 293T cells transiently transfected with authentic SARS-2 spike were lysed by human NK-92 cells in the presence of control antibody CR3022 or RAY53, but not an isotype control (<xref ref-type="fig" rid="fig5">Figure 5d</xref>). These results indicate that RAY53 binding is compatible with ADCP and ADCC, although the impact of RAY53-mediated effector functions on disease progression requires future evaluation in animal models.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Antibodies binding S2 are an important component of the immune response to SARS-CoV-2 and other coronavirus infections. They are naturally elicited, with neutralizing sera from individuals never exposed to SARS-2 common in young people and exclusively binding the S2 domain (<xref ref-type="bibr" rid="bib40">Ng et al., 2020</xref>). This S2 response is boosted upon exposure to SARS-2 (<xref ref-type="bibr" rid="bib17">Dowell et al., 2022</xref>). These antibodies are generally common in convalescent repertoires, with &gt;300 anti-S2 sequences reported (<xref ref-type="bibr" rid="bib49">Raybould et al., 2021</xref>), but with few detailed descriptions and just two epitope classes defined. Antibodies recognizing the SARS-2 S2 stem region between residues 1142–1160, proximal to the viral membrane, (<xref ref-type="bibr" rid="bib29">Hsieh et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Pinto et al., 2021</xref>; <xref ref-type="bibr" rid="bib51">Sauer et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Ullah et al., 2021</xref>; <xref ref-type="bibr" rid="bib62">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib36">Li et al., 2022</xref>; <xref ref-type="bibr" rid="bib71">Zhou et al., 2022</xref>) dominate linear S2 peptide responses (<xref ref-type="bibr" rid="bib35">Ladner et al., 2021</xref>) but generally result in moderate-to-no neutralization of SARS-2 spike pseudovirus (10 to &gt;300 nM IC<sub>50</sub>). Antibodies binding the fusion peptide, which mediates steps required for viral entry of host cells, are highly cross-reactive to α- and β-coronavirus spike proteins, typically neutralize SARS-2 pseudoviruses (<xref ref-type="bibr" rid="bib38">Low et al., 2022</xref>) and authentic viruses (<xref ref-type="bibr" rid="bib15">Dacon et al., 2022</xref>) with modest in vitro IC<sub>50</sub> values &gt;50 nM. Antibodies binding the hinge epitope in the S2 core are much less thoroughly described, although antibodies isolated from unexposed individuals that appear to bind near the hinge epitope based on negative staining EM images were enriched 37-fold upon infection (<xref ref-type="bibr" rid="bib10">Claireaux et al., 2022</xref>). An emerging theme is that highly conserved S2 epitopes, whether located at the stem, fusion peptide or hinge, are immunogenic but often fail to mediate strong antibody neutralization (<xref ref-type="bibr" rid="bib6">Bowen et al., 2021</xref>).</p><p>By contrast, antibodies targeting these highly conserved S2 epitopes seem to rely heavily on Fc effector functions to mediate protection by antibody-dependent viral phagocytosis, cellular cyto-toxicity, and/or trogocytosis of infected cells. The S2 stem binding antibodies S2P6 (<xref ref-type="bibr" rid="bib47">Pinto et al., 2021</xref>) and IgG22 (<xref ref-type="bibr" rid="bib29">Hsieh et al., 2021</xref>) protected SARS-2 challenged animals in vivo. IgG22 did not neutralize authentic virus in vitro, implicating Fc functions in protection in vivo, and S2P6 was shown to elicit ADCP and ADCC in vitro. Partial protection in a prophylaxis mouse model by stem-binding antibody CV3-25 was ablated by residues changes that silence the Fc (<xref ref-type="bibr" rid="bib57">Ullah et al., 2021</xref>). Similarly, antibodies binding the fusion peptide moderately protected hamsters against severe disease (<xref ref-type="bibr" rid="bib15">Dacon et al., 2022</xref>; <xref ref-type="bibr" rid="bib38">Low et al., 2022</xref>). S2 core-binding antibodies require further validation, but those found in the human repertoire elicited ADCP and antibody-dependent cellular trogocytosis in vitro (<xref ref-type="bibr" rid="bib10">Claireaux et al., 2022</xref>) while the hinge-binding antibody RAY53 reported here induced ADCP and ADCC in vitro (<xref ref-type="fig" rid="fig5">Figure 5c and d</xref>). Highly conserved S2 epitopes may be underappreciated targets based on simple neutralization assays, but valuable for eliciting effector functions against many variants, similar to antibodies binding the flu stem region (<xref ref-type="bibr" rid="bib31">Impagliazzo et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Corti et al., 2017</xref>).</p><p>The presence of S2 core-binding antibodies in the naïve immune repertoire and their amplification after infection with pre-Omicron strains of SARS-2 suggests that S2 core epitopes exerted immune pressure in early waves of COVID-19 infection. Antibody RAY53’s dramatic loss of binding to authentic SARS-2 Omicron BA.1 spike (<xref ref-type="fig" rid="fig4">Figure 4d</xref>) is consistent with evolutionary evasion of antibodies binding the S2 core as the virus has been repeatedly exposed to the human immune response. While antibody evasion by the SARS-2 spike commonly occurs through substitutions within targeted epitopes (<xref ref-type="bibr" rid="bib24">Greaney et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Starr et al., 2021</xref>), SARS-2 Omicron BA.1 contains only one residue change within the hinge epitope which does not alter RAY53 binding in isolation (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). Antibody RAY53 binds soluble Omicron BA.1 HexaPro spike, albeit with a depressed on-rate (<xref ref-type="fig" rid="fig4">Figure 4c</xref>, <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4f</xref>), but did not bind authentic Omicron BA.1 spike on the cell surface or neutralize the corresponding pseudovirus (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). Omicron BA.1 appears to protect cryptic epitopes by closely packing the RBDs in the down state and possibly stabilizing the S2-closed state when RBDs are up for ACE2 binding. This structural protection may be evolutionarily favored over mutation when altering the epitope sequence carries a high functional cost, as for the hinge epitope (<xref ref-type="fig" rid="fig3">Figure 3d</xref>).</p><p>SARS-2 spike is a highly dynamic protein, sensitive to many variables including temperature (<xref ref-type="bibr" rid="bib19">Edwards et al., 2021</xref>), pH (<xref ref-type="bibr" rid="bib70">Zhou et al., 2020</xref>), and glycosylation (<xref ref-type="bibr" rid="bib9">Casalino et al., 2020</xref>). Each of the RBDs has the potential to flip up, which has been captured in cryo-EM images of closed, one-up, two-up, and three-up spikes (<xref ref-type="bibr" rid="bib4">Benton et al., 2020</xref>). Additionally, molecular dynamics simulations indicated that movement of the S1 domains during opening extends deeper into the protein than previously appreciated (<xref ref-type="bibr" rid="bib72">Zimmerman et al., 2021</xref>), while HDX analysis has observed an open-S2 conformation with a splayed spike trimer that exposes core S2 epitopes (<xref ref-type="bibr" rid="bib13">Costello et al., 2022</xref>). Notably, these movements impact hinge epitope accessibility, indicating that antibody binding to this region involves multiple kinetic steps (<xref ref-type="fig" rid="fig2">Figure 2f</xref>). Data showing enhanced binding to spike variants favoring the S2 open state (<xref ref-type="fig" rid="fig2">Figure 2c–e</xref>) and similar neutralization of authentic spike on pseudo-viruses by 3A3 and RAY53 (<xref ref-type="fig" rid="fig5">Figure 5a</xref>) despite the latter’s increased affinity (<xref ref-type="fig" rid="fig4">Figure 4e</xref>) indicate that spike S2 opening is the rate-limiting step in antibody binding. Results shown here also underscore that these rates can vary depending on the local environment (soluble protein versus viral or infected cell surface) and amino acid changes present (stabilizing changes versus circulating variants), highlighting the importance of spike dynamics on antibody binding.</p><p>Here, we report an S2 hinge epitope that is conserved across all highly pathogenic coronavirus strains and its interactions with two related antibodies. Immunization with 2P-stabilized spike and natural infection appears to elicit antibodies binding this epitope in the S2 core, but antibody access is restricted by spike dynamics that expose the epitope. Although targeting this epitope alone is unlikely to be potently neutralizing, strategies that enhance access to the highly conserved S2 core such as ACE2-mimicking antibodies (<xref ref-type="bibr" rid="bib38">Low et al., 2022</xref>) may allow existing antibody repertoires to more effectively promote viral clearance by recruiting Fc effector functions. Future work will use these conformationally-selective antibodies to elucidate spike behavior in response to stabilizing and evolved mutations as well as environmental conditions including spike surface density, protease priming, and interactions with other cellular or viral membrane proteins.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-NP 1C7C7</td><td align="left" valign="bottom">Thomas Moran (The Icahn School of Medicine at Mount Sinai)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-spike CR3022</td><td align="left" valign="bottom">Constructed based on <xref ref-type="bibr" rid="bib56">ter Meulen et al., 2006</xref>.</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-spike mAb 2–4</td><td align="left" valign="bottom">Constructed based on <xref ref-type="bibr" rid="bib37">Liu et al., 2020</xref> .</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-spike S309</td><td align="left" valign="bottom">Constructed based on <xref ref-type="bibr" rid="bib46">Pinto et al., 2020</xref>.</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-StrepTagII Fab (clone C23.21)</td><td align="left" valign="bottom">Constructed based on patent WO2015067768A1 (Institut Pasteur)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Antibody variants: 3A3, hu3A3, RAY53, 3E11</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Sequences can be found in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti human κ HRP</td><td align="left" valign="bottom">SouthernBiotech</td><td align="left" valign="bottom">Cat# 2060-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti human IgG Fc-AF647</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 109-605-008</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti mouse Ig HRP</td><td align="left" valign="bottom">SouthernBiotech</td><td align="left" valign="bottom">Cat# 1010-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-human IgG Fc-HRP (polyclonal)</td><td align="left" valign="bottom">SouthernBiotech</td><td align="left" valign="bottom">Cat# 2047-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Human Fab<sub>2</sub> anti-strep-tag (clone C23.21)</td><td align="left" valign="bottom">Jason McLellan Lab</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse anti c-myc, clone 9E10</td><td align="left" valign="bottom">BioXCell</td><td align="left" valign="bottom">Cat #MA1-980</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse anti FLAG (M2) HRP</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A8592</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse anti FLAG (M2) PE</td><td align="left" valign="bottom">BioLegend/Prozyme</td><td align="left" valign="bottom">Cat# 637309/ #PJ315</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse anti-M13 pVIII-HRP, clone RL-pH1</td><td align="left" valign="bottom">Santa Cruz Biotech</td><td align="left" valign="bottom">Cat# sc53004</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Cricetulus griseus</italic>)</td><td align="left" valign="bottom">CHO-T</td><td align="left" valign="bottom">Acyte BioTech</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="bottom">CHOK-1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CCL-61</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>C. griseus</italic>)</td><td align="left" valign="bottom">ExpiCHO</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A29133</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Expi293</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A41249</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Freestyle HEK293-F</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# R79007</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK-293T-hACE2</td><td align="left" valign="bottom">BEI Resources</td><td align="left" valign="bottom">Cat# NR-52511</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">NK-92 V158</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# PTA-8836</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">THP-1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# TIB-202</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Vero HL</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib45">Piepenbrink et al., 2022</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Biotin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# B4501-10G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Calcein AM</td><td align="left" valign="bottom">BD Pharmingen</td><td align="left" valign="bottom">Cat# 564061</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Flash Red 1μ Beads</td><td align="left" valign="bottom">Bangs Laboratories</td><td align="left" valign="bottom">Cat# FSFR004</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">pHrodo iFL Green STP Ester</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# P36013</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TMB Substrate</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 34021</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Alexa Fluor 647 Protein Labelling Kit</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# A20173</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ExpiFectamine 293 Transfection Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A14524</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ExpiFectamine CHO Transfection Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A29129</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">HiTrap Protein A columns</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">Cat# 17-5498-54P</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">IMAC Sepharose 6 Fast Flow resin</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">Cat# 17092107</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Lipofectamine 2000</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 11668019</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mycostrip test</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">Cat# rep-mys-10</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Octet Anti-Human Fab-CH1 2nd Generation (FAB2G) Biosensors</td><td align="left" valign="bottom">Forte Bio</td><td align="left" valign="bottom">Cat# 18-5125</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Octet Streptavidin (SA) Biosensor</td><td align="left" valign="bottom">Forte Bio</td><td align="left" valign="bottom">Cat# 18-5019</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Protein Thermal Shift Dye Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 4461146</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Series S Sensor Chip CM5</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">Cat# BR100530</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Strep-Tactin XT Superflow high capacity cartridge</td><td align="left" valign="bottom">IBA</td><td align="left" valign="bottom">Cat# 2-4026-001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Superdex 200 Increase 10/300GL</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">Cat# 28-9909-44</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Organisms (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Balb/c mice</td><td align="left" valign="bottom">Charles River</td><td align="left" valign="bottom">Cat# 028</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">HBS EP+buffer</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">Cat# BR100669</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Avidin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A9275-25MG</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Streptavidin AF647</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 016600084</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Streptavidin PE</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 405204</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">AbVec hIgG1</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib53">Smith et al., 2009</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">AbVec hIgKappa</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib53">Smith et al., 2009</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">HDM-IDTSpike-fixK</td><td align="left" valign="bottom">BEI Resources</td><td align="left" valign="bottom">Cat# NR-52514</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">M13KO7 helper phage (virus)</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">N0315S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1(-)- Wuhan-Hu-1 Spike</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib60">Walls et al., 2020</xref><break/>BEI Resources</td><td align="left" valign="bottom">Cat# NR-52420</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV-VSV-G</td><td align="left" valign="bottom">Cell Biolabs</td><td align="left" valign="bottom">Cat# RV-110</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCTCon-Fab</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib61">Wang et al., 2018</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pHAGE-CMV-Luc2-IRS-ZsGreen-W</td><td align="left" valign="bottom">BEI Resources</td><td align="left" valign="bottom">Cat# NR-52516</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pHAGE2-EF1aInt-ACE2-WT</td><td align="left" valign="bottom">BEI Resources</td><td align="left" valign="bottom">Cat# NR-52512</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEX307-DPP4-G418</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat# 158453</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMoPac24</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Hayhurst et al., 2003</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primers for cloning mouse variable regions</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">Krebber et al., 1997</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Astra Software V6.1.2</td><td align="left" valign="bottom">Wyatt Technology</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016255">SCR_016255</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Biacore X100 Evaluation Software V2.0.1</td><td align="left" valign="bottom">GE Healthcare</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cisTEM</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib23">Grant et al., 2018</xref></td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016502">:SCR_016502</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cryoSPARC</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib48">Punjani et al., 2017</xref></td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016501">:SCR_016501</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DynamX v3.0</td><td align="left" valign="bottom">Waters</td><td align="left" valign="bottom">Part# 720005145en</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Excel 1808</td><td align="left" valign="bottom">Microsoft</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib52">Schindelin et al., 2012</xref></td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">:SCR_002285</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo 10.7.1</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">:SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism, v9.2.0</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Motulsky and Brown, 2006</xref></td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">:SCR_002285</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">HD-eXplosion v 1.2</td><td align="left" valign="bottom">Naifu Zhang and Sheena D’Arcy (The University of Texas at Dallas)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Image J v1.53e</td><td align="left" valign="bottom">NIH</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Octet Data Analysis Software V11.1</td><td align="left" valign="bottom">Forte Bio</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ViiA 7 Software</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">DH5α electrocompetent cells</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# C2987H</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>E. coli</italic>)</td><td align="left" valign="bottom">XL1-Blue</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat# 200228</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Saccharomyces cerevisiae</italic>)</td><td align="left" valign="bottom">AYW101</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib64">Wentz and Shusta, 2007</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>S. cerevisiae</italic>)</td><td align="left" valign="bottom">EBY100 yeast</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# MYA-4941</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Nomenclature</title><p>In this work, ‘spike’ refers to the extracellular coronavirus fusogen domains containing homologous 2P changes (proline substitutions at residues 986 and 987 in SARS-CoV-2) C-terminally fused to a foldon domain (<xref ref-type="bibr" rid="bib65">Wrapp et al., 2020a</xref>), whereas ‘authentic’ refers to spike variants as expressed without stabilizing changes as found on the virion, with other variations noted. ‘Wild-type’ SARS-CoV-2 spike refers to the spike sequence originally reported in January of 2020 for ancestral (Wuhan-Hu-1, GenBank accession number MN908947) SARS-CoV-2. For brevity and clarity, ‘SARS-2’ refers to the SARS-CoV-2 virus or spike, ‘SARS-1’ to SARS-CoV, and ‘MERS’ to MERS-CoV henceforth.</p></sec><sec id="s4-2"><title>Cell lines</title><p>Eukaryotic cell lines were obtained from the sources listed in the reagent table above under ‘Cell lines.’ No commonly misidentified cell lines were used in this study. Cell lines were purchased from reputable suppliers for protein expression and not further authenticated with the exception of HEK-293T-hACE2 cells, which were generated in the lab. These cells were verified to express human ACE2 after lentiviral infection and selection by Western blot as described in the text. Cell lines growing in the lab are tested approximately once per year for mycoplasma contamination using InvivoGen’s MycoStrip test, with no contamination detected.</p></sec><sec id="s4-3"><title>Spike expression</title><p>Soluble coronavirus spikes and spike variants were expressed and purified as previously described (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Wrapp et al., 2020b</xref>). SARS-2 (<xref ref-type="bibr" rid="bib65">Wrapp et al., 2020a</xref>), SARS-1 (<xref ref-type="bibr" rid="bib32">Kirchdoerfer et al., 2018</xref>), SARS-2 HexaPro (<xref ref-type="bibr" rid="bib28">Hsieh et al., 2020</xref>), MERS (<xref ref-type="bibr" rid="bib43">Pallesen et al., 2017</xref>), HKU1 (<xref ref-type="bibr" rid="bib43">Pallesen et al., 2017</xref>), and variant spikes were expressed in ExpiCHO or Freestyle 293F cells (Thermo Fisher Scientific). MERS S2 included residues 763–1291 of MERS-2P with 8 additional stabilizing substitutions (<xref ref-type="bibr" rid="bib29">Hsieh et al., 2021</xref>). SARS-2 HexaPro S2 included residues 697–1208 of the SARS-2 spike with an artificial signal peptide, proline substitutions at positions 817, 892, 899, 942, 986, and 987 and a C-terminal T4 fibritin domain, HRV3C cleavage site, 8×HisTag and TwinStrepTag. HexaPro RBD-locked-down (<xref ref-type="bibr" rid="bib67">Xiong et al., 2020</xref>) included the substitutions S383C-D985C in SARS-2 HexaPro. Aglycosylated HexaPro was produced by treating SARS-2 HexaPro with Endo H overnight at 4°C leaving only one N-acetylglucosamine attached to N-glycosylation site.</p></sec><sec id="s4-4"><title>Murine immunization</title><p>Three 6-week-old female BALB/c (Charles River labs, Cat# 028) mice were immunized subcutaneously with 5 μg prefusion stabilized MERS S2 and 20 μg of ODN1826 + 100 μl of 2× Sigma Adjuvant System (SAS; Sigma) containing monophosphoryl lipid A and trehalose dimycolate in squalene oil. Four weeks later, the mice were boosted with the same dose of the same mixture. Three weeks after boosting, the mice were sacrificed and spleens were collected in RNALater (Thermo Fisher). All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols approved by the University of Texas at Austin (protocol AUP-2018-00092).</p></sec><sec id="s4-5"><title>Phage display antibody library construction</title><p>RNA from each mouse was isolated from the aqueous phase of homogenized spleens mixed with 1-bromo-3-chloropropane and purified with the PureLink RNA kit (Invitrogen) separately. The Superscript IV kit (Invitrogen) was used to synthesize cDNA. The V<sub>H</sub> and V<sub>L</sub> sequences from each immunized mouse were amplified with mouse-specific primers described by <xref ref-type="bibr" rid="bib34">Krebber et al., 1997</xref>. Maintaining separate reactions for each mouse, the V<sub>L</sub> and V<sub>H</sub> regions were joined by overlap extension PCR to generate V<sub>L</sub>-linker-V<sub>H</sub> fragments (scFv) in which the linker region encodes the amino acids (Gly<sub>4</sub>Ser)<sub>4</sub> and <italic>Sfi</italic>I sites flanked the scFv sequence. The scFv PCR products were pooled and cloned into pMopac24 (<xref ref-type="bibr" rid="bib25">Hayhurst et al., 2003</xref>) via <italic>Sfi</italic>I cut sites to encode an scFv with a c-terminal myc tag fused to the M13 phage pIII protein. This library was then transformed to XL1-Blue (Agilent Technologies) <italic>Escherichia coli</italic>. The total number of transformants was 3.1 × 10<sup>8</sup> with &lt;0.01% background based on plating.</p></sec><sec id="s4-6"><title>Phage display and panning</title><p>The <italic>E. coli</italic> containing the library were expanded in growth media (2×YT with 1% glucose, 200 μg/mL ampicillin, 10 μg/mL tetracycline) at 37°C to an OD<sub>600</sub> of 0.5, then infected with 1 × 10<sup>11</sup> pfu/mL M13K07 helper phage (NEB) and induced with 1 mM isopropyl β-d-1-thiogalactopyranoside. After 2 hr of shaking at room temperature, 12.5 μg/mL of kanamycin was added for phage expression overnight. Phage were precipitated in 20% PEG-8000 in 2.5 M NaCl, titered by infection of XL1-Blue and plating, and used for Round 1 panning. This process was repeated for each round of panning, starting from overnight growth of the output phage from each round.</p><p>Four rounds of panning were used to isolate scFvs binding both MERS S2 and SARS-2 spike using the following solutions coated on high binding plates: 2 μg/mL anti-c-myc tag antibody (Invitrogen) to eliminate phage expressing no or truncated scFv (round 1), 2 μg/mL MERS S2 (round 2), 2 μg/mL SARS-2 spike (round 3), and 0.4 μg/mL SARS-2 spike (round 4). In each round of panning, the plates were blocked with 5% non-fat milk in phosphate-buffered saline (PBS) with 0.05% Tween-20 (PBS-T), and phage were preincubated with 5% non-fat milk in PBS-T for 30 min before incubation on the plate for 1.5 hr at room temperature. After thorough washing with PBS-T, output phage was eluted using 0.1 M HCl at pH 2.2, neutralized with ~1:20 2 M Tris base, and allowed to infect XL1-Blue cells overnight amplification.</p><p>Random clones isolated after rounds 3 and 4 of panning were sequenced and unique clones were tested by monoclonal phage enzyme-linked immunosorbent assay (ELISA) on plates coated with SARS-2 spike or RSV F foldon at 2 μg/mL in PBS. Briefly, plates were coated overnight at 4°C, washed with PBS-T, then blocked with PBS-T and 5% milk. Phage were allowed to bind for 1 hr at room temperature, thoroughly washed with PBS-T, then incubated with 1:2000 anti-M13 pVIII-HRP (GE Healthcare) in PBS-T 5% milk for another hour. After washing, the plate was developed with the TMB Substrate Kit (Thermo Scientific), quenched with an equal volume of 1 M HCl and evaluated by absorbance at 450 nm.</p></sec><sec id="s4-7"><title>Antibody expression, purification, and quality control</title><p>Full-length antibody versions of 3A3 and 3E11 were cloned as previously described (<xref ref-type="bibr" rid="bib41">Nguyen et al., 2015</xref>) as mouse variable region-human IgG1 constant region chimeras. Antibodies hu3A3 and RAY53 were similarly cloned into human IgG1 and IgΚ expression vectors. Antibodies were expressed in ExpiCHO (Thermo Fisher Scientific) cells according to the high titer protocol provided and purified on a Protein A HiTrap column (GE Healthcare) with the ACTA Pure FPLC system (GE Healthcare), and buffer exchanged to PBS.</p><p>Human Fab fragments were generated by digestion of full-length antibody with papain and removal of the Fc portion by protein A binding. Mouse Fab fragments of 3A3 were generated by cloning the V<sub>H</sub> and V<sub>L</sub> regions upstream of heavy chain constant regions with a HRV3C protease site in the hinge (<xref ref-type="bibr" rid="bib43">Pallesen et al., 2017</xref>) and a mouse kappa chain, respectively. After expression, protein A purified protein was digested with HRV3C protease, and the flow-through from a protein A HiTrap column was collected. Excess HRV3C protease was removed by incubation with Ni Sepharose 6Fast Flow beads (GE Healthcare). Fully murine antibodies were produced by cloning the V<sub>H</sub> regions into mouse IgG2a and V<sub>L</sub> regions in to a mouse IgK expression cassettes in the pAbVec background, co-transfecting, and purifying as described above.</p></sec><sec id="s4-8"><title>Hydrogen-deuterium exchange mass spectrometry</title><p>Hydrogen-deuterium exchange was performed on complexes were formed with excess antibody (0.50 μM SARS-2 HexaPro spike protein alone or in the presence of 0.55 μM 3A3 IgG or Fab) such that the SARS-2 HexaPro spike was expected to be ~90% bound based on the known protein concentrations and measured K<sub>d</sub>. Only spike protein peptides were analyzed in this experiment. Complexes were thawed from –80°C storage on ice and incubated for 10 min at 25°C before exchange in 90% deuterium and 20 mM Tris pH 8.0, 200 mM NaCl. The exchange was quenched after 10<sup>1</sup>, 10<sup>2</sup>, 10<sup>3</sup>, and 10<sup>4</sup> s by mixing samples 1:1 with cooled 0.2% (v/v) formic acid, 200 mM TCEP, 8 M Urea, pH 2.3. Samples were immediately flash-frozen in liquid N<sub>2</sub> and stored at −80°C. Hydrogen-deuterium exchange was similarly performed on 0.50 μM 3A3 IgG alone or in the presence of 0.75 μM of SARS-2 HexaPro spike protein. Only 3A3 IgG peptides were analyzed in this experiment. Samples were prepared as described above, but in 86% deuterium for 10<sup>1</sup>, 10<sup>2</sup>, and 10<sup>3</sup> s.</p><p>Samples were thawed and LC-MS performed using a Waters HDX manager and SYNAPT G2-<italic>Si</italic> Q-Tof. Three or four technical replicates of each sample were analyzed in random order. Samples were digested online by <italic>Sus scrofa</italic> Pepsin A (Waters Enzymate BEH Pepsin column) at 15°C and peptides trapped on a C18 pre-column (Waters ACQUITY UPLC BEH C18 VanGuard pre-column) at 1°C for 3 min at 100 μL/min. Peptides were separated over a C18 column (Waters ACQUITY UPLC BEH C18 column) and eluted with a linear 3–40% (v/v) Acetonitrile gradient for 7 min at 30 uL/min at 1°C and 0.1% (v/v) formic acid as the basic LC buffer.</p><p>MS data were acquired using positive ion mode and either HDMS or HDMS<sup>E</sup>. HDMS<sup>E</sup> mode was used to collect both low (6 V) and high (ramping 22–44 V) energy fragmentation data for peptide identification in water-only samples. HDMS mode was used to collect low-energy ion data for all deuterated samples. All samples were acquired in resolution mode. The capillary voltage was set to 2.8 kV for the sample sprayer. Desolvation gas was set to 650 L/hr at 175°C. The source temperature was set to 80°C. Cone and nebulizer gas were flowed at 90 L/hr and 6.5 bar, respectively. The sampling cone and source offset were set to 30 V. Data were acquired at a scan time of 0.4 s with a range of 100–2000 m/z. A mass correction was done using [Glu1]-fibrinopeptide B as a reference mass.</p><p>Water-only control samples were processed by Protein Lynx Global Server v.3.0.2 with a ‘minimum fragment ion matches per peptide’ of 3 and allowing methionine oxidation. The low and elevated energy thresholds were 250 and 50 counts, respectively, and the overall intensity threshold was 750 counts. The resulting peptide lists were then used to search data from deuterated samples using DynamX v.3.0. We did not search for glycosylated peptides as de-glycosylation had little impact on 3A3 binding (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4f</xref>). Peptide filters of 0.3 products per amino acid and one consecutive product were used. Spectra were manually assessed, and figures were prepared using HD-eXplosion (<xref ref-type="bibr" rid="bib69">Zhang et al., 2020</xref>) and PyMOL (<xref ref-type="bibr" rid="bib16">DeLano, 2002</xref>). The HDX data summary table (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) and complete data table (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) are included. The location of the 3A3 epitope was confirmed in a separate experiment carried out over the temperature range of 4–37°C (<xref ref-type="bibr" rid="bib13">Costello et al., 2022</xref>).</p></sec><sec id="s4-9"><title>Low-resolution cryo-EM</title><p>To form spike-antibody complex, prefusion-stabilized SARS-CoV-2 S2 was incubated with 1.5-fold molar excess of 3A3 Fab at room temperature for 20 min. The mixture was then applied to a size-exclusion column (SEC) in a running buffer containing 2 mM Tris pH 8.0, 200 mM NaCl, and 0.02% NaN<sub>3</sub> to obtain a peak fraction containing the S2-3A3 Fab complex for cryo-EM sample preparation. The complex at 0.5 mg/mL was deposited on a plasma-cleaned Au-Flat 1.2/1.3 grid (ProtoChip), which was plunge-frozen using a Vitrobot Mark IV (Thermo Fisher) with 4 s blot time and –2 force at 100% humidity at 22°C. A total of 1179 micrographs were collected using a Glacios (Thermo Fisher) equipped with a Falcon IV direct electron detector. Data were collected at a magnification of 150,000×, corresponding to a calibrated pixel size of 0.94 Å/pix. CryoSPARC v3.2.0 was used for patch motion correction, CTF estimation, particle picking, and particle curation via iterative rounds of 2D classification (<xref ref-type="bibr" rid="bib48">Punjani et al., 2017</xref>). One class that had the best-resolved 3D reconstruction from heterogenous refinement was used for subsequent non-uniform homogeneous refinement. ChimeraX (<xref ref-type="bibr" rid="bib44">Pettersen et al., 2021</xref>) was used to generate a mask that encompassed the Fab and the apex of an S2 protomer to perform focused refinement. A protomer of SARS-CoV-2 spike (PDB: 6XKL) without the S1 subunit and an ABodyBuilder-predicted 3A3 Fab structure (<xref ref-type="bibr" rid="bib18">Dunbar et al., 2016</xref>) was used as a model to dock into the local EM map generated by focused refinement using cryoSPARC v3.2.0.</p></sec><sec id="s4-10"><title>Biolayer interferometry (BLI) and surface plasmon resonance (SPR) measurements</title><p>To evaluate ACE2 binding to HexaPro captured by 3A3, AHC anti-human IgG Fc (ForteBio) sensors were used to pick up 3A3 (10 nM) to a response of 0.6 nm. Then mAb-coated tips were dipped into wells containing HexaPro (50 nM) to a response of 0.6 nm and then dipped into wells containing ACE2 (50 nM), irrelevant murine mAb (50 nM), or buffer. Association of mu3A3/irrelevant mAb was measured for 5 min and dissociation for 10 min.</p><p>To compare 3A3 and mAb 2–4 binding to HexaPro and ‘Down’ HexaPro, AHC anti-human IgG Fc (ForteBio) sensors were loaded with 3A3 or mAb 2–4 mAb in the kinetics buffer at 10 nM to a response of 0.6 nm. After a baseline step, the sensors were incubated with either HexaPro or ‘Down’ HexaPro, both at 60 nM for 5 min. Dissociation step was recorded for 10 min in the kinetics buffer.</p><p>To determine the affinity of 3A3 Fab by BLI, AHC anti-human IgG Fc (ForteBio) sensors were coated with the anti-foldon antibody identified in this work (3E11) at 10 nM in the kinetics buffer (0.01% BSA and 0.002% Tween-20 in PBS) to a response of 0.6 nm. MAb-coated sensors were then incubated with HexaPro S2 at 60 nM to a response of 0.6 nm. Association of 3A3 Fab was recorded for 5 min in kinetics buffer, starting at 100 nM followed by 1:2 dilutions. The dissociation was recorded for 10 min in the kinetics buffer. K<sub>d</sub> values were obtained using a 1:1 global fit model using the Octet instrument software. 3A3 Fab kinetics measurement was repeated once.</p><p>To determine the on-rate (<italic>k</italic><sub>on</sub>) values for 3A3 and RAY53 binding to various spike constructs, AHC anti-human IgG Fc (ForteBio) sensors were loaded with 10 nM antibody in kinetics buffer to a response of 0.6 nm. Association curves were recorded by incubating the sensors in spike, serial diluted 1:2. The dissociation step was recorded in the kinetics buffer without spike. On-rate values were determined using the 1:1 association non-linear fit on GraphPad prism 9.4.1 with off-rates constrained to 1 × 10<sup>–12</sup> s<sup>–1</sup>.</p><p>For all BLI experiments, an Octet Red96 (ForteBio) instrument was used. Between every loading step, sensors were washed with kinetics buffer for 30 s. Before use, sensors were hydrated in the kinetics buffer for 10 min. After each assay, the sensors were regenerated using 10 mM Glycine, pH 1.5.</p><p>SPR was used to determine the binding kinetics and equilibrium affinity of the 3A3 Fab and HexaPro S2 interaction as well as the RAY53 and 4P-DS. An anti-StrepTagII Fab (clone C23.21) was covalently coupled to a CM5 sensor chip in 10 mM sodium acetate at pH 4.0 for a final RU of ~4300. It was then used to capture purified SARS-2 HexaPro S2 or 4P-DS by the c-terminal twin StrepTag to ~80 or ~1000 response units (RU), respectively, in each cycle using a Biacore X100 (GE Healthcare). The binding surface was regenerated between cycles using 0.1% SDS followed by 10 mM glycine at pH 2. The IgG or Fab was serially diluted and injected over the blank reference flow cell and then SARS-2 HexaPro S2- or 4P-DS-coated flow cell in HBS-P+ buffer. Buffer was also injected through both flow cells as a reference. The data were double-reference subtracted and fit to a 1:1 binding model using BIAevaluation software.</p></sec><sec id="s4-11"><title>ELISA evaluation of antibody binding</title><p>ELISAs were in either a spike or antibody capture configuration as indicated. For spike capture, plates were coated with 1 μg/mL of purified spike proteins in PBS. Duplicate serial dilutions of each full-length antibody in PBS-T with 5% milk were allowed to bind each coat, and the secondary antibody solution was a 1:1200 dilution of goat-anti-human IgG Fc-HRP (SouthernBiotech). For antibody capture, antibody was coated at 1 μg/mL in PBS. Duplicate serial dilutions of spike in PBS-T with 3% bovine serum albumin were allowed to bind each coat, and the secondary antibody solution was a 1:2000 dilution of streptactin-HRP (IBA Lifesciences). ELISA curves were fit to a four-parameter logistic curve.</p><p>Fresh aliquots of SARS-2 and SARS-2 HexaPro spikes were thawed and split to stress the spike proteins. One half of the aliquot was stressed by incubation at –20°C for 5 min, then 50°C for 2 min for three temperature cycles. The freshly thawed and stressed spikes were evaluated in antibody capture ELISAs. For each fresh and stressed spike, 8 µg was analyzed by SDS-PAGE under non-reducing conditions.</p></sec><sec id="s4-12"><title>Humanization of 3A3</title><p>Humanized 3A3 V<sub>H</sub> and V<sub>L</sub> regions were designed as previously described (<xref ref-type="bibr" rid="bib41">Nguyen et al., 2015</xref>), and the variable regions were cloned into human IgK and IgG1 expression plasmids. The heavy and light chains were transfected together into ExpiCHO cells for combinatorial analysis of expression level and HexaPro binding. The veneering method of humanization for both V<sub>L</sub> and V<sub>H</sub> resulted in binding equivalent to 3A3 with slightly improved expression.</p></sec><sec id="s4-13"><title>Yeast display and engineering of 3A3</title><p>The hu3A3 light chain and Fab heavy chain region were cloned into pCTCON-Fab (<xref ref-type="bibr" rid="bib61">Wang et al., 2018</xref>) with the heavy chain fused to Aga2 and a c-Myc tag and c-terminal FLAG tag on the light chain. The V<sub>H</sub> and V<sub>L</sub> regions were subjected to random mutagenesis at a target rate of 0.3%. In parallel, a site-directed library was created using primers encoding degenerate codons at CDRL2 and CDRH3 locations implicated in spike binding by HDX. Both the random and site-directed PCR products were integrated into <italic>Saccharomyces cerevisiae</italic> strain AWY101 (<xref ref-type="bibr" rid="bib64">Wentz and Shusta, 2007</xref>) yeast plasmid by homologous recombination as previously described (<xref ref-type="bibr" rid="bib3">Benatuil et al., 2010</xref>), resulting in approximately 3 × 10<sup>7</sup> variants in each library. Libraries and transformed yeast were grown and maintained in YNB media with casamino acids and 2% glucose at 30°C.</p><p>To induce expression of surface displayed Fab, yeast were subcultured to an OD<sub>600</sub> of 0.5 in YNB media with casamino acids, 0.2% glucose and 1.8% galactose and allowed to grow for 24 hr at 25°C. Libraries were sorted for three or four rounds by staining with 1:200 anti-FLAG-R-PE (ProZyme) and 50 nM 4P-DS directly labeled with Alexa Fluor 647 (Thermo Fisher) for 15 min at room temperature and 45 min on ice, and the brightest AF647 cells also fluorescent in the PE channel were sorted on a SONY MA900 cell sorter. Individual clones were isolated and the variable regions from the most promising 4P-DS binding yeast clones were amplified and transferred to mammalian expression vectors. Heavy and light chain candidates were transfected for combinatorial screening and evaluated for binding to 4P-DS by ELISA. RAY53 was the highest binding clone isolated and is comprised of a light chain variable region originating from the site-directed library and a heavy chain from the random mutagenesis library.</p></sec><sec id="s4-14"><title>Western blot of antibody binding to coronavirus spike proteins</title><p>Purified coronavirus spike proteins were reduced and boiled, and 50 ng of each was subjected to SDS-PAGE and transfer to PVDF membranes in duplicate. After blocking with PBS-T with 5% milk, the membranes were probed with 0.2 μg/mL 3A3 or 3E11 for 1 hr at room temperature. After washing with PBS-T, the membranes were incubated with 1:4000 goat anti-human IgG Fc-HRP for 45 min at room temperature, then developed with the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and imaged.</p></sec><sec id="s4-15"><title>Mammalian expression and lentiviral plasmids</title><p>Plasmids required for mammalian expression and lentiviral production were obtained from BEI Resources. Plasmids expressing the HIV virion under the CMV promotor (HDM-Hgpm2, pRC-CMV-Rev1b, and HDM-tat1b) were provided under the following catalog numbers NR-52517, NR-52519, and NR-52518, respectively (<xref ref-type="bibr" rid="bib14">Crawford et al., 2020</xref>). Plasmids for lentiviral backbone expressing a luciferase reporter under the CMV promotor followed by an IRES and ZsGreen (pHAGE-CMV-Luc2-IRS-ZsGreen-W) or human ACE2 gene (GenBank ID NM_021804) under an EF1a promoter (pHAGE2-EF1aInt-ACE2-WT) were provided as NR-52516 and NR52512, respectively (<xref ref-type="bibr" rid="bib14">Crawford et al., 2020</xref>). The envelop vector expressing a codon-optimized wild-type SARS-2 spike protein (GenBank ID NC_045512) under a CMV promoter was obtained from BEI resources (HDM-IDTSpike-fixK, NR-52514, called pWT-SARS-2-spike here) (<xref ref-type="bibr" rid="bib14">Crawford et al., 2020</xref>) The lentiviral backbone vector expressing a human DPP4 gene under an EF1a promoter (pLEX307-DPP4-G418) was obtained from Addgene, while the plasmid expressing VSV G (vesicular stomatitis virus glycoprotein) was purchased from Cell Biolabs (pCMV-VSV-G, Part No. RV-110). The pWT-SARS-2-spike plasmid was employed as a template for site-directed mutagenesis to generate the expression plasmid for the D614G and D614G with D985L, E988Q, or E988A. SARS-2 Omicron BA.1 (B.1.1.529) Spike Gene ORF cDNA was purchased from SinoBiological Inc SARS-2 Omicron BA.1, SARS-1 and MERS spike sequences were cloned into the pWT-SARS-2-spike plasmid for pseudovirus production.</p></sec><sec id="s4-16"><title>Flow cytometric evaluation of antibody binding to mammalian surface displayed spike</title><p>On day 0, Expi-293 cells (Thermo Fisher) were transfected with pEGFP alone or pEGFP and pWT-SARS-2-spike in a 1:1 ratio. On day 2, RAY53 in concentrations ranging from 300 nM to 3.5 nM was used to stain ~3 × 10<sup>5</sup> transfected cells for 1 hr on ice. All cells were collected, washed with PBS with 1% FBS, then incubated with 1:250 goat-anti-human Fc-PE for 1 hr on ice. Cells were washed again, then scanned for EGFP and PE fluorescence on a BD Fortessa flow cytometer, and analyzed with FlowJo. Cells were gated by FSC and SSC, singlets, then EGFP expression to only analyze transfected cells. The PE GMFI of the EGFP expressing cells at each concentration was then used to calculate the effective K<sub>d</sub> as described (<xref ref-type="bibr" rid="bib20">Feldhaus and Siegel, 2004</xref>).</p><p>To assess RAY53 binding to additional spike variants, Expi-293 cells were transfected with either pWT-SARS-2-spike, pOmicronBA1-SARS-2-spike, pSARS-spike, or pMERS-spike (no pEGFP plasmid was used) and treated as described above. Either 100 nM of RAY53 or 10 nM S309 was used to stain the transfected cells before incubation with goat-anti-human Fc-PE.</p></sec><sec id="s4-17"><title>Confocal cell fusion assay</title><p>On day 0, the CHO-T cells (Acyte Biotech) were transfected with either pPyEGFP (<xref ref-type="bibr" rid="bib42">Nguyen et al., 2018</xref>) or 1:4 pWT-SARS- CoV-2-spike:pPyEGFP using Lipofectamine 2000 (Life Technologies), and media was replaced on day 1. On day 2 after transfection, HEK-293T-hACE2 cells (BEI, NR-52511), which stably expresses human ACE2, were stained with 1 μM CellTrace Far Red dye (Invitrogen, Ex/Em: 630/661 nm) in PBS for 20 min at room temperature, then quenched with DMEM with 10% heat-inactivated FBS for 5 min, and resuspended in fresh media. CHO-T cells expressing EGFP or EGFP and surface spike were preincubated with the antibody for 1 hr at 37°C, then mixed with HEK-hACE2 cells at a ratio of 5:1 in 24-well plates with a coverslip on the bottom of each well. On day 3, after 20 hr of coincubation, the coverslip with bound cells was washed once with PBS and fixed with 4% paraformaldehyde for 20 min at room temperature, washed again, and mounted on slides with DAPI-fluoromount-G (SouthernBiotech). Images were collected with Zeiss LSM 710 confocal microscope (Carl Zeiss, Inc) and processed using ImageJ software (<ext-link ext-link-type="uri" xlink:href="http://rsbweb.nih.gov/ij">http://rsbweb.nih.gov/ij</ext-link>).</p><p>Two different statistical analysis methods determined the cell fusion level. The first statistical analysis was based on the percentage of HEK-ACE2 pixels (red) colocalizing with spike expressing CHO pixels (green), which was determined by the following equation within the JACoP plugin for ImageJ (<xref ref-type="bibr" rid="bib5">Bolte and Cordelières, 2006</xref>):<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">K</mml:mi><mml:mo>−</mml:mo><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">z</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mrow><mml:mi mathvariant="normal">%</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mtext> </mml:mtext><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mtext> </mml:mtext><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mtext> </mml:mtext><mml:mn>633</mml:mn><mml:mtext> </mml:mtext><mml:mi>n</mml:mi><mml:mi>m</mml:mi><mml:mtext> </mml:mtext><mml:mi>w</mml:mi><mml:mi>a</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mtext> </mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:mi>H</mml:mi><mml:mi>E</mml:mi><mml:mi>K</mml:mi><mml:mo>−</mml:mo><mml:mi>A</mml:mi><mml:mi>C</mml:mi><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mtext> </mml:mtext><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>x</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mtext> </mml:mtext><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mtext> </mml:mtext><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mtext> </mml:mtext><mml:mi>C</mml:mi><mml:mi>H</mml:mi><mml:mi>O</mml:mi><mml:mtext> </mml:mtext><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>x</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mtext> </mml:mtext><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mtext> </mml:mtext><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mtext> </mml:mtext><mml:mn>633</mml:mn><mml:mtext> </mml:mtext><mml:mi>n</mml:mi><mml:mi>m</mml:mi><mml:mtext> </mml:mtext><mml:mi>w</mml:mi><mml:mi>a</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mtext> </mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:mi>H</mml:mi><mml:mi>E</mml:mi><mml:mi>K</mml:mi><mml:mo>−</mml:mo><mml:mi>A</mml:mi><mml:mi>C</mml:mi><mml:mi>E</mml:mi><mml:mn>2</mml:mn><mml:mtext> </mml:mtext><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mi>x</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>The colocalization percentage for each independent image was determined using the Manders’ coefficient. The average HEK-ACE2 cell size after coincubation with CHO cells was also determined using ImageJ software. The images collected at 633 nm emission (red fluorescence) were converted into 16-bit grayscale and the threshold adjusted to highlight the cell structure. The average cell size was automatically counted using ‘Analyze Particles’ with a size threshold (50–infinity) to exclude the background noise. The cells on the edge were excluded. The statistical significance of either HEK-ACE2 colocalization percentage or average cell size between different conditions was calculated with ANOVA using GraphPad Prism 7 (GraphPad Software). Values represent the mean and standard deviation of at least 160 cells.</p></sec><sec id="s4-18"><title>Generation of HEK293T-ACE2 and HEK293T-DPP4 target cells</title><p>A lentiviral vector expressing human ACE2 (pHAGE2-EF1aInt-ACE2-WT) or DPP4 (pLEX307-DPP4-G418) an EF1a promoter was used to transduce HEK293T cells. Clonal selection depended on the susceptibility to infection by the pseudotyped lentiviral particles; selected clones were validated using Western blotting.</p></sec><sec id="s4-19"><title>SARS-2 spike-mediated pseudovirus entry assay</title><p>HIV particles pseudotyped with wild-type or the Omicron BA.1 variant of SARS-2 spike, SARS-1 spike, MERS spike, and VSV-G were generated in HEK 293T cells. A detailed protocol for generating these particles was reported by <xref ref-type="bibr" rid="bib14">Crawford et al., 2020</xref>. HEK 293T cells were co-transfected with plasmids for (1) HIV virion-formation proteins (HDM-Hgpm2, pRC-CMV-Rev1b, and HDM-tat1b); (2) lentiviral backbone expressing luciferase reporter (pHAGE-CMV-Luc2-IRES-ZsGreen-W); and (3) a plasmid encoding one of the envelope proteins (wild-type SARS-2, SARS-2 Omicron BA.1, SARS-1, MERS, or VSV G). 72 hours post-transfection, media containing the pseudovirus particles were collected, filtered, fractionated, and stored at –80°C. In all the assays, 10,000 target cells were seeded in each well of the 96-well plate and allowed to adhere overnight before virus treatment. For the SARS-2-spike mutagenesis studies, virus titer was estimated for each virus using the qPCR Lentivirus Titer Kit (abm LV900), following the manufacturer’s protocol. An equal number of viral particles carrying each spike mutant were serially diluted and added directly to HEK293T-ACE2 target cells (in triplicate). For the neutralization assays, the particles were used directly in cell entry experiments or after pre-incubation with each antibody for one hour at room temperature or at 4°C for the viral particles pseudotyped with the MERS spike. After 60–72 hr, a total number of cells per well were estimated using lncuCyte ZOOM equipment with a ×10 objective. Then cells were treated with the Bright-Glo Luciferase Assay reagent (Promega, E2610) to detect a luciferase signal (relative luciferase units or RLU) following the manufacturer’s protocol. The percentage of entry was estimated as the ratio of the relative luciferase units recorded in the presence and absence of the tested antibody and a half-maximal inhibitory concentration (IC<sub>50</sub>) calculated using a three-parameter logistic regression equation (GraphPad Prism v9.0).</p></sec><sec id="s4-20"><title>Live SARS-2 viral neutralization assays</title><p>Approximately 200 PFU/well of SARS-2 WA-1 strain containing twofold dilutions (starting concentration 670 nM) of antibody were incubated at 37°C for 1 hr. Vero HL cells (4 × 10<sup>4</sup> cells/well in quadruplicate) were infected with the virus/antibody mixture, or virus alone mixture for 1 hr. After 1 hr virus adsorption, the media was changed with post-infection media containing 2% FBS, 1% Avicel and antibody. At 24 hr post-infection, infected and mock infected control cells were fixed with 10% neutral formalin for 24 hr and were immunostained with the anti-NP monoclonal 1C7C7 antibody. Virus neutralization was evaluated and quantified using ELISPOT, and the percentage of infectivity calculated using sigmoidal dose–response curves. In both cases, mock-infected cells and viruses in the absence of antibody were used as internal controls. Dotted line indicates 50% neutralization. Data were expressed as mean and SD.</p></sec><sec id="s4-21"><title>Fc-dependent ADCP and ADCC assays</title><p>To assess the ability of antibodies to induce phagocytosis, Flash Red polystyrene beads (Bangs Laboratories) were coated with SARS-2 HexaPro or 4P-DS spike and stained with pHrodo Green (Thermo Fisher Scientific). The beads were incubated with 50,000 undifferentiated THP-1 cells at a ratio of 50:1, and antibodies at 3.4 nM for 4 hr at 37°C. After washing, 10,000 cells per sample were evaluated by flow cytometry on a BD Fortessa instrument for red (APC channel) and pHrodo Green fluorescence. The phagocytosis score was calculated as the percent of total cells fluorescent in both the APC and pHrodo Green channel multiplied by the GMFI for the APC channel (<xref ref-type="bibr" rid="bib1">Ackerman et al., 2011</xref>). Data was collected from two separate experiments with two technical replicates each.</p><p>To evaluate ADCC, HEK-293T cells were transfected with pWT-SARS-2-spike or nothing (mock) and allowed to express surface spike for 2 days. The HEK-293T cells were then stained with 2 µM calcein AM (BD Biosciences) for 30 min in serum-free media at 37°C, washed thoroughly and incubated for 4 hr with 67 nM antibody and NK-92 V158 cells (ATCC) at a ratio of 10:1. The cells were then spun down. The fluorescence of the supernatant was measured with 488 nm excitation and 515 nm emission. Controls included HEK-293T cells alone (spontaneous release) and fully lysed with detergent (maximum lysis). The following calculation determined the percent lysis for each antibody:<disp-formula id="equ3"><mml:math id="m3"><mml:mrow><mml:mi mathvariant="normal">%</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mtext> </mml:mtext><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>U</mml:mi><mml:mo>−</mml:mo><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mtext> </mml:mtext><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mtext> </mml:mtext><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>U</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mtext> </mml:mtext><mml:mi>l</mml:mi><mml:mi>y</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mtext> </mml:mtext><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>U</mml:mi><mml:mo>−</mml:mo><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mtext> </mml:mtext><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mtext> </mml:mtext><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>U</mml:mi></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Three assays were performed in total with duplicate technical replicates.</p></sec><sec id="s4-22"><title>Statistical analyses</title><p>The means ± SD were determined for all appropriate data. For the mammalian cell fusion experiments, pseudovirus neutralization experiments and epitope variant analysis, a one-way analysis of variance (ANOVA) with Tukey’s simultaneous test with p-values was used to determine statistical significance between groups. Welch’s <italic>t</italic>-test was used to determine the significance of deuterium uptake differences.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>is an inventor on U.S. patent application no. 63/135,913 (&quot;Cross-reactive antibodies recognizing the coronavirus spike S2 domain&quot;)</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an inventor on U.S. patent application no. 63/135,913 (&quot;Cross-reactive antibodies recognizing the coronavirus spike S2 domain&quot;). inventors on patent no. WO/2021/243122 and PCT/US2021/034713 (&quot;Engineered Coronavirus Spike (S) Protein and Methods of Use Thereof&quot;). Is an inventor on U.S. patent application no. 63/188,813 (&quot;Stabilized S2 Beta-coronavirus Antigens')</p></fn><fn fn-type="COI-statement" id="conf3"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf4"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf5"><p>inventor on patent no. WO/2021/243122 and PCT/US2021/034713 (&quot;Engineered Coronavirus Spike (S) Protein and Methods of Use Thereof&quot;)</p></fn><fn fn-type="COI-statement" id="conf6"><p>inventor on U.S. patent application no. 63/135,913 (&quot;Cross-reactive antibodies recognizing the coronavirus spike S2 domain&quot;). J.S.M. is an inventor on U.S. patent application no. 62/412,703 (&quot;Prefusion Coronavirus Spike Proteins and Their Use&quot;) and U.S. patent application no. 62/972,886 (&quot;2019-nCoV Vaccine&quot;). Is an inventor on patent no. WO/2021/243122 and PCT/US2021/034713 (&quot;Engineered Coronavirus Spike (S) Protein and Methods of Use Thereof&quot;). Is an inventor on U.S. patent application no. 63/188,813 (&quot;Stabilized S2 Beta-coronavirus Antigens')</p></fn><fn fn-type="COI-statement" id="conf7"><p>inventor on U.S. patent application no. 63/135,913 (&quot;Cross-reactive antibodies recognizing the coronavirus spike S2 domain&quot;) and WO/2021/243122 and PCT/US2021/034713 (&quot;Engineered Coronavirus Spike (S) Protein and Methods of Use Thereof&quot;)</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Methodology</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Investigation</p></fn><fn fn-type="con" id="con14"><p>Resources</p></fn><fn fn-type="con" id="con15"><p>Resources</p></fn><fn fn-type="con" id="con16"><p>Resources</p></fn><fn fn-type="con" id="con17"><p>Resources</p></fn><fn fn-type="con" id="con18"><p>Investigation</p></fn><fn fn-type="con" id="con19"><p>Investigation</p></fn><fn fn-type="con" id="con20"><p>Investigation</p></fn><fn fn-type="con" id="con21"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con22"><p>Supervision, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con23"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con24"><p>Supervision, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con25"><p>Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con26"><p>Conceptualization, Supervision, Funding acquisition, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols approved by The University of Texas at Austin (protocol AUP-2018-00092).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>HDX summary table for antibody peptides.</title></caption><media xlink:href="elife-83710-supp1-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Complete HDX data for spike and antibody peptides.</title></caption><media xlink:href="elife-83710-supp2-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Width of isotopic distributions for example spike peptides.</title><p>Peptides were selected from regions identified as having bimodal distributions in Costello et al. We had no coverage in residues 626–636 and 1146–1166. Peak width (PW) in Da was calculated in triplicate for each peptide in the non-deuterated sample (ND Control) and at each time point of exchange. The SD is reported. The change in peak width (ΔPW) was calculated by subtracting the PW of the control from the PW of the sample. Bimodality was assessed by taking the maximum peak width for a particular peptide (ΔPWmax) and assessing if it was greater than 2 Da. Peak width was calculated using a method similar to <xref ref-type="bibr" rid="bib63">Weis et al., 2006</xref>. Peptides were centroided with the Apex3D algorithm using DynamX (Waters). Following manual curation, ion stick data were transferred into Excel as two columns of data, m/z values and intensities, and the maximum peak in the isotopic envelope was determined. The list was then searched in descending m/z order to identify the two lowest m/z peaks that straddled 20% of the maximum peak intensity. The m/z value at an envelope intensity of 20% of the maximum intensity was determined using linear interpolation between these two peaks. This process was repeated with a search in ascending m/z order. The relative peak width was determined by multiplying by z (the charge state). For peptide spectra without peaks straddling 20% of the maximum peak intensity on one side of the maximum, typical for lower m/z peaks for peptides exhibiting low deuteration, the farthest isotopic centroid peak on that side was used as the m/z limit for calculating peak width while the other m/z limit was determined using the previously described method.</p></caption><media xlink:href="elife-83710-supp3-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Antibody variable region sequences.</title></caption><media xlink:href="elife-83710-supp4-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83710-mdarchecklist1-v3.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files. Sequences of the novel antibodies reported (3A3, RAY53 and 3E11) are provided in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The following reagent was contributed by David Veesler for distribution through BEI Resources, NIAID, NIH: Vector pcDNA3.1(-) containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike Glycoprotein Gene, NR-52420 (<xref ref-type="bibr" rid="bib60">Walls et al., 2020</xref>). The following reagents were obtained through BEI Resources, NIAID, NIH: Human Embryonic Kidney Cells (HEK-293T) Expressing Human Angiotensin-Converting Enzyme 2, HEK-293T-hACE2 Cell Line, NR-52511; SARS-Related Coronavirus 2, Wuhan-Hu-1 Spike-Pseudotyped Lentiviral Kit, NR-52948 (including NR-52514, NR-52516, NR-52517, NR-51518, and NR-52519); and Vector pHAGE2 Containing the ZsGreen Gene, NR-52520. The authors would like to thank Erin Scherer for the plasmids encoding SARS-2 Delta HexaPro stabilized spike; Kamyab Javanmardi, Thomas H Segall-Shapiro, and Jimmy D Gollihar for the plasmid encoding SARS-2 Omicron BA.1 HexaPro stabilized spike; Thomas Moran for antibody 1C7C7; Alejandro Chavez and Sho Iketani for the plasmid pLEX307-DPP4-G418 (Addgene plasmid #158453); and Eric Shusta for the yeast strain AWY101. The authors would like to thank Gregory C Ippolito, Jason J Lavinder, Ilya Finkelstein, and George Delidakis for useful discussions and advice related to this work. Flow cytometry and confocal microscopy was performed at the Center for Biomedical Research Support Microscopy and Imaging Facility at UT Austin (RRID# SCR_021756). The authors gratefully acknowledge all data contributors for generating the SARS-CoV-2 genetic sequence and metadata and sharing them via the GISAID Initiative, on which some of our analysis was based. This work was supported by NIH grants AI127521 (JSM), GM133751 (SD), and AI122753 (JAM), the Bill &amp; Melinda Gates Foundation INV-017592 (JSM and JAM); Welch Foundation grants F-1767 (JAM), F-0003-19620604 (JSM), F-1390 (KD), and AT-2059-20210327 (SD); NSF RAPID 2027066 (JAM), NSF GRFP (ANQ and AMD); and a University of Texas at Austin Texas Biologics grant to JAM and JSM. This research was supported, in part, by the UT System Proteomics Network (SD). SM is a Chan Zuckerberg Biohub Investigator.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackerman</surname><given-names>ME</given-names></name><name><surname>Moldt</surname><given-names>B</given-names></name><name><surname>Wyatt</surname><given-names>RT</given-names></name><name><surname>Dugast</surname><given-names>AS</given-names></name><name><surname>McAndrew</surname><given-names>E</given-names></name><name><surname>Tsoukas</surname><given-names>S</given-names></name><name><surname>Jost</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>CT</given-names></name><name><surname>Sciaranghella</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples</article-title><source>Journal of Immunological Methods</source><volume>366</volume><fpage>8</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2010.12.016</pub-id><pub-id pub-id-type="pmid">21192942</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Jette</surname><given-names>CA</given-names></name><name><surname>Abernathy</surname><given-names>ME</given-names></name><name><surname>Dam</surname><given-names>KMA</given-names></name><name><surname>Esswein</surname><given-names>SR</given-names></name><name><surname>Gristick</surname><given-names>HB</given-names></name><name><surname>Malyutin</surname><given-names>AG</given-names></name><name><surname>Sharaf</surname><given-names>NG</given-names></name><name><surname>Huey-Tubman</surname><given-names>KE</given-names></name><name><surname>Lee</surname><given-names>YE</given-names></name><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-cov-2 neutralizing antibody structures inform therapeutic strategies</article-title><source>Nature</source><volume>588</volume><fpage>682</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2852-1</pub-id><pub-id pub-id-type="pmid">33045718</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benatuil</surname><given-names>L</given-names></name><name><surname>Perez</surname><given-names>JM</given-names></name><name><surname>Belk</surname><given-names>J</given-names></name><name><surname>Hsieh</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An improved yeast transformation method for the generation of very large human antibody libraries</article-title><source>Protein Engineering, Design &amp; Selection</source><volume>23</volume><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1093/protein/gzq002</pub-id><pub-id pub-id-type="pmid">20130105</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benton</surname><given-names>DJ</given-names></name><name><surname>Wrobel</surname><given-names>AG</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Roustan</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>SR</given-names></name><name><surname>Rosenthal</surname><given-names>PB</given-names></name><name><surname>Skehel</surname><given-names>JJ</given-names></name><name><surname>Gamblin</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Receptor binding and priming of the spike protein of SARS-cov-2 for membrane fusion</article-title><source>Nature</source><volume>588</volume><fpage>327</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2772-0</pub-id><pub-id pub-id-type="pmid">32942285</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolte</surname><given-names>S</given-names></name><name><surname>Cordelières</surname><given-names>FP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A guided tour into subcellular colocalization analysis in light microscopy</article-title><source>Journal of Microscopy</source><volume>224</volume><fpage>213</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2818.2006.01706.x</pub-id><pub-id pub-id-type="pmid">17210054</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>JE</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Joshi</surname><given-names>A</given-names></name><name><surname>Sprouse</surname><given-names>KR</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Franko</surname><given-names>NM</given-names></name><name><surname>Logue</surname><given-names>JK</given-names></name><name><surname>Mazzitelli</surname><given-names>IG</given-names></name><name><surname>Tiles</surname><given-names>SW</given-names></name><name><surname>Ahmed</surname><given-names>K</given-names></name><name><surname>Shariq</surname><given-names>A</given-names></name><name><surname>Snell</surname><given-names>G</given-names></name><name><surname>Iqbal</surname><given-names>NT</given-names></name><name><surname>Geffner</surname><given-names>J</given-names></name><name><surname>Bandera</surname><given-names>A</given-names></name><name><surname>Gori</surname><given-names>A</given-names></name><name><surname>Grifantini</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name><name><surname>Van Voorhis</surname><given-names>WC</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-Cov-2 Spike Conformation Determines Plasma Neutralizing Activity</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.12.19.473391</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Sterling</surname><given-names>SM</given-names></name><name><surname>Walsh</surname><given-names>RM</given-names><suffix>Jr</suffix></name><name><surname>Rawson</surname><given-names>S</given-names></name><name><surname>Rits-Volloch</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct conformational states of SARS-cov-2 spike protein</article-title><source>Science</source><volume>369</volume><fpage>1586</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1126/science.abd4251</pub-id><pub-id pub-id-type="pmid">32694201</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Bowen</surname><given-names>JE</given-names></name><name><surname>Rosen</surname><given-names>LE</given-names></name><name><surname>Saliba</surname><given-names>C</given-names></name><name><surname>Zepeda</surname><given-names>SK</given-names></name><name><surname>Culap</surname><given-names>K</given-names></name><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>VanBlargan</surname><given-names>LA</given-names></name><name><surname>De Marco</surname><given-names>A</given-names></name><name><surname>di Iulio</surname><given-names>J</given-names></name><name><surname>Zatta</surname><given-names>F</given-names></name><name><surname>Kaiser</surname><given-names>H</given-names></name><name><surname>Noack</surname><given-names>J</given-names></name><name><surname>Farhat</surname><given-names>N</given-names></name><name><surname>Czudnochowski</surname><given-names>N</given-names></name><name><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name><surname>Sprouse</surname><given-names>KR</given-names></name><name><surname>Dillen</surname><given-names>JR</given-names></name><name><surname>Powell</surname><given-names>AE</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Maher</surname><given-names>C</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Soriaga</surname><given-names>L</given-names></name><name><surname>Bassi</surname><given-names>J</given-names></name><name><surname>Silacci-Fregni</surname><given-names>C</given-names></name><name><surname>Gustafsson</surname><given-names>C</given-names></name><name><surname>Franko</surname><given-names>NM</given-names></name><name><surname>Logue</surname><given-names>J</given-names></name><name><surname>Iqbal</surname><given-names>NT</given-names></name><name><surname>Mazzitelli</surname><given-names>I</given-names></name><name><surname>Geffner</surname><given-names>J</given-names></name><name><surname>Grifantini</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Gori</surname><given-names>A</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name><name><surname>Giannini</surname><given-names>O</given-names></name><name><surname>Ceschi</surname><given-names>A</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Cippà</surname><given-names>PE</given-names></name><name><surname>Franzetti-Pellanda</surname><given-names>A</given-names></name><name><surname>Garzoni</surname><given-names>C</given-names></name><name><surname>Halfmann</surname><given-names>PJ</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Hebner</surname><given-names>C</given-names></name><name><surname>Purcell</surname><given-names>LA</given-names></name><name><surname>Piccoli</surname><given-names>L</given-names></name><name><surname>Pizzuto</surname><given-names>MS</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Snell</surname><given-names>G</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Broadly neutralizing antibodies overcome SARS-cov-2 omicron antigenic shift</article-title><source>Nature</source><volume>602</volume><fpage>664</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04386-2</pub-id><pub-id pub-id-type="pmid">35016195</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casalino</surname><given-names>L</given-names></name><name><surname>Gaieb</surname><given-names>Z</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hjorth</surname><given-names>CK</given-names></name><name><surname>Dommer</surname><given-names>AC</given-names></name><name><surname>Harbison</surname><given-names>AM</given-names></name><name><surname>Fogarty</surname><given-names>CA</given-names></name><name><surname>Barros</surname><given-names>EP</given-names></name><name><surname>Taylor</surname><given-names>BC</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Fadda</surname><given-names>E</given-names></name><name><surname>Amaro</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Beyond shielding: the roles of glycans in the SARS-cov-2 spike protein</article-title><source>ACS Central Science</source><volume>6</volume><fpage>1722</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.0c01056</pub-id><pub-id pub-id-type="pmid">33140034</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claireaux</surname><given-names>M</given-names></name><name><surname>Caniels</surname><given-names>TG</given-names></name><name><surname>de Gast</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Guerra</surname><given-names>D</given-names></name><name><surname>Kerster</surname><given-names>G</given-names></name><name><surname>van Schaik</surname><given-names>BDC</given-names></name><name><surname>Jongejan</surname><given-names>A</given-names></name><name><surname>Schriek</surname><given-names>AI</given-names></name><name><surname>Grobben</surname><given-names>M</given-names></name><name><surname>Brouwer</surname><given-names>PJM</given-names></name><name><surname>van der Straten</surname><given-names>K</given-names></name><name><surname>Aldon</surname><given-names>Y</given-names></name><name><surname>Capella-Pujol</surname><given-names>J</given-names></name><name><surname>Snitselaar</surname><given-names>JL</given-names></name><name><surname>Olijhoek</surname><given-names>W</given-names></name><name><surname>Aartse</surname><given-names>A</given-names></name><name><surname>Brinkkemper</surname><given-names>M</given-names></name><name><surname>Bontjer</surname><given-names>I</given-names></name><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Poniman</surname><given-names>M</given-names></name><name><surname>Bijl</surname><given-names>TPL</given-names></name><name><surname>Torres</surname><given-names>JL</given-names></name><name><surname>Copps</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>IC</given-names></name><name><surname>de Taeye</surname><given-names>SW</given-names></name><name><surname>de Bree</surname><given-names>GJ</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Sliepen</surname><given-names>K</given-names></name><name><surname>van Kampen</surname><given-names>AHC</given-names></name><name><surname>Moerland</surname><given-names>PD</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>van Gils</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>4539</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-32232-0</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AA</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Greaney</surname><given-names>AJ</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Starr</surname><given-names>TN</given-names></name><name><surname>Keeffe</surname><given-names>JR</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Schulz</surname><given-names>JE</given-names></name><name><surname>Gnanapragasam</surname><given-names>PNP</given-names></name><name><surname>Kakutani</surname><given-names>LM</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Saturday</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>YE</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Jette</surname><given-names>CA</given-names></name><name><surname>Lewis</surname><given-names>MG</given-names></name><name><surname>Tan</surname><given-names>TK</given-names></name><name><surname>Townsend</surname><given-names>AR</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mosaic RBD Nanoparticles Protect against Multiple Sarbecovirus Challenges in Animal Models</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.03.25.485875</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Guarino</surname><given-names>B</given-names></name><name><surname>Kallewaard</surname><given-names>NL</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tackling influenza with broadly neutralizing antibodies</article-title><source>Current Opinion in Virology</source><volume>24</volume><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.03.002</pub-id><pub-id pub-id-type="pmid">28527859</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname><given-names>SM</given-names></name><name><surname>Shoemaker</surname><given-names>SR</given-names></name><name><surname>Hobbs</surname><given-names>HT</given-names></name><name><surname>Nguyen</surname><given-names>AW</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Maynard</surname><given-names>JA</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Pak</surname><given-names>JE</given-names></name><name><surname>Marqusee</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The SARS-cov-2 spike reversibly samples an open-trimer conformation exposing novel epitopes</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>29</volume><fpage>229</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/s41594-022-00735-5</pub-id><pub-id pub-id-type="pmid">35236990</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>KHD</given-names></name><name><surname>Eguia</surname><given-names>R</given-names></name><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Loes</surname><given-names>AN</given-names></name><name><surname>Malone</surname><given-names>KD</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Pettie</surname><given-names>D</given-names></name><name><surname>King</surname><given-names>NP</given-names></name><name><surname>Balazs</surname><given-names>AB</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Protocol and reagents for pseudotyping lentiviral particles with SARS-cov-2 spike protein for neutralization assays</article-title><source>Viruses</source><volume>12</volume><elocation-id>513</elocation-id><pub-id pub-id-type="doi">10.3390/v12050513</pub-id><pub-id pub-id-type="pmid">32384820</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dacon</surname><given-names>C</given-names></name><name><surname>Tucker</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>CCD</given-names></name><name><surname>Lin</surname><given-names>TH</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Cong</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Purser</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>JK</given-names></name><name><surname>Pyo</surname><given-names>CW</given-names></name><name><surname>Kosik</surname><given-names>I</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Mohan</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>AJR</given-names></name><name><surname>Peterson</surname><given-names>M</given-names></name><name><surname>Skinner</surname><given-names>J</given-names></name><name><surname>Dixit</surname><given-names>S</given-names></name><name><surname>Kollins</surname><given-names>E</given-names></name><name><surname>Huzella</surname><given-names>L</given-names></name><name><surname>Perry</surname><given-names>D</given-names></name><name><surname>Byrum</surname><given-names>R</given-names></name><name><surname>Lembirik</surname><given-names>S</given-names></name><name><surname>Drawbaugh</surname><given-names>D</given-names></name><name><surname>Eaton</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Weinberg</surname><given-names>RS</given-names></name><name><surname>Pegu</surname><given-names>A</given-names></name><name><surname>Geraghty</surname><given-names>DE</given-names></name><name><surname>Davidson</surname><given-names>E</given-names></name><name><surname>Douagi</surname><given-names>I</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>Schmaljohn</surname><given-names>C</given-names></name><name><surname>Crompton</surname><given-names>PD</given-names></name><name><surname>Holbrook</surname><given-names>MR</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Broadly neutralizing antibodies target the coronavirus fusion peptide</article-title><source>Science</source><volume>377</volume><fpage>728</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1126/science.abq3773</pub-id><pub-id pub-id-type="pmid">35857439</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>DeLano</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2002">2002</year><data-title>The pymol molecular graphics system</data-title><publisher-name>DeLano Scientific</publisher-name><ext-link ext-link-type="uri" xlink:href="https://pymol.sourceforge.net/overview/index.htm">https://pymol.sourceforge.net/overview/index.htm</ext-link></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowell</surname><given-names>AC</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Jinks</surname><given-names>E</given-names></name><name><surname>Tut</surname><given-names>G</given-names></name><name><surname>Lancaster</surname><given-names>T</given-names></name><name><surname>Sylla</surname><given-names>P</given-names></name><name><surname>Begum</surname><given-names>J</given-names></name><name><surname>Bruton</surname><given-names>R</given-names></name><name><surname>Pearce</surname><given-names>H</given-names></name><name><surname>Verma</surname><given-names>K</given-names></name><name><surname>Logan</surname><given-names>N</given-names></name><name><surname>Tyson</surname><given-names>G</given-names></name><name><surname>Spalkova</surname><given-names>E</given-names></name><name><surname>Margielewska-Davies</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>GS</given-names></name><name><surname>Syrimi</surname><given-names>E</given-names></name><name><surname>Baawuah</surname><given-names>F</given-names></name><name><surname>Beckmann</surname><given-names>J</given-names></name><name><surname>Okike</surname><given-names>IO</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Garstang</surname><given-names>J</given-names></name><name><surname>Brent</surname><given-names>AJ</given-names></name><name><surname>Brent</surname><given-names>B</given-names></name><name><surname>Ireland</surname><given-names>G</given-names></name><name><surname>Aiano</surname><given-names>F</given-names></name><name><surname>Amin-Chowdhury</surname><given-names>Z</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Borrow</surname><given-names>R</given-names></name><name><surname>Linley</surname><given-names>E</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Azad</surname><given-names>R</given-names></name><name><surname>Waiblinger</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Thomson</surname><given-names>EC</given-names></name><name><surname>Palmarini</surname><given-names>M</given-names></name><name><surname>Willett</surname><given-names>BJ</given-names></name><name><surname>Barclay</surname><given-names>WS</given-names></name><name><surname>Poh</surname><given-names>J</given-names></name><name><surname>Amirthalingam</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>KE</given-names></name><name><surname>Ramsay</surname><given-names>ME</given-names></name><name><surname>Zuo</surname><given-names>J</given-names></name><name><surname>Moss</surname><given-names>P</given-names></name><name><surname>Ladhani</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-cov-2 infection</article-title><source>Nature Immunology</source><volume>23</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01089-8</pub-id><pub-id pub-id-type="pmid">34937928</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunbar</surname><given-names>J</given-names></name><name><surname>Krawczyk</surname><given-names>K</given-names></name><name><surname>Leem</surname><given-names>J</given-names></name><name><surname>Marks</surname><given-names>C</given-names></name><name><surname>Nowak</surname><given-names>J</given-names></name><name><surname>Regep</surname><given-names>C</given-names></name><name><surname>Georges</surname><given-names>G</given-names></name><name><surname>Kelm</surname><given-names>S</given-names></name><name><surname>Popovic</surname><given-names>B</given-names></name><name><surname>Deane</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SAbPred: a structure-based antibody prediction server</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W474</fpage><lpage>W478</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw361</pub-id><pub-id pub-id-type="pmid">27131379</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>RJ</given-names></name><name><surname>Mansouri</surname><given-names>K</given-names></name><name><surname>Stalls</surname><given-names>V</given-names></name><name><surname>Manne</surname><given-names>K</given-names></name><name><surname>Watts</surname><given-names>B</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Janowska</surname><given-names>K</given-names></name><name><surname>Gobeil</surname><given-names>SMC</given-names></name><name><surname>Kopp</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Mu</surname><given-names>Z</given-names></name><name><surname>Deyton</surname><given-names>M</given-names></name><name><surname>Oguin</surname><given-names>TH</given-names></name><name><surname>Sprenz</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>W</given-names></name><name><surname>Saunders</surname><given-names>KO</given-names></name><name><surname>Montefiori</surname><given-names>D</given-names></name><name><surname>Sempowski</surname><given-names>GD</given-names></name><name><surname>Henderson</surname><given-names>R</given-names></name><name><surname>Munir Alam</surname><given-names>S</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cold sensitivity of the SARS-cov-2 spike ectodomain</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>28</volume><fpage>128</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-00547-5</pub-id><pub-id pub-id-type="pmid">33402708</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldhaus</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Flow cytometric screening of yeast surface display libraries</article-title><source>Methods in Molecular Biology</source><volume>263</volume><fpage>311</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1385/1-59259-773-4:311</pub-id><pub-id pub-id-type="pmid">14976374</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromant</surname><given-names>M</given-names></name><name><surname>Blanquet</surname><given-names>S</given-names></name><name><surname>Plateau</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction</article-title><source>Analytical Biochemistry</source><volume>224</volume><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1006/abio.1995.1050</pub-id><pub-id pub-id-type="pmid">7710092</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobeil</surname><given-names>SMC</given-names></name><name><surname>Henderson</surname><given-names>R</given-names></name><name><surname>Stalls</surname><given-names>V</given-names></name><name><surname>Janowska</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>May</surname><given-names>A</given-names></name><name><surname>Speakman</surname><given-names>M</given-names></name><name><surname>Beaudoin</surname><given-names>E</given-names></name><name><surname>Manne</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Barr</surname><given-names>M</given-names></name><name><surname>Deyton</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Mansouri</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>RJ</given-names></name><name><surname>Sempowski</surname><given-names>GD</given-names></name><name><surname>Saunders</surname><given-names>KO</given-names></name><name><surname>Wiehe</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>W</given-names></name><name><surname>Korber</surname><given-names>B</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural diversity of the SARS-cov-2 omicron spike</article-title><source>Molecular Cell</source><volume>82</volume><fpage>2050</fpage><lpage>2068</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.03.028</pub-id><pub-id pub-id-type="pmid">35118469</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>T</given-names></name><name><surname>Rohou</surname><given-names>A</given-names></name><name><surname>Grigorieff</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>cistem, user-friendly software for single-particle image processing</article-title><source>eLife</source><volume>7</volume><elocation-id>e35383</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.35383</pub-id><pub-id pub-id-type="pmid">29513216</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaney</surname><given-names>AJ</given-names></name><name><surname>Starr</surname><given-names>TN</given-names></name><name><surname>Barnes</surname><given-names>CO</given-names></name><name><surname>Weisblum</surname><given-names>Y</given-names></name><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Cho</surname><given-names>A</given-names></name><name><surname>Agudelo</surname><given-names>M</given-names></name><name><surname>Finkin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Poston</surname><given-names>D</given-names></name><name><surname>Muecksch</surname><given-names>F</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name><name><surname>Robbiani</surname><given-names>DF</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mapping mutations to the SARS-cov-2 RBD that escape binding by different classes of antibodies</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>4196</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24435-8</pub-id><pub-id pub-id-type="pmid">34234131</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayhurst</surname><given-names>A</given-names></name><name><surname>Happe</surname><given-names>S</given-names></name><name><surname>Mabry</surname><given-names>R</given-names></name><name><surname>Koch</surname><given-names>Z</given-names></name><name><surname>Iverson</surname><given-names>BL</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis</article-title><source>Journal of Immunological Methods</source><volume>276</volume><fpage>185</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/s0022-1759(03)00100-5</pub-id><pub-id pub-id-type="pmid">12738372</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>RJ</given-names></name><name><surname>Mansouri</surname><given-names>K</given-names></name><name><surname>Janowska</surname><given-names>K</given-names></name><name><surname>Stalls</surname><given-names>V</given-names></name><name><surname>Gobeil</surname><given-names>SMC</given-names></name><name><surname>Kopp</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Hsu</surname><given-names>AL</given-names></name><name><surname>Borgnia</surname><given-names>MJ</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Controlling the SARS-cov-2 spike glycoprotein conformation</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>925</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0479-4</pub-id><pub-id pub-id-type="pmid">32699321</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossen</surname><given-names>ML</given-names></name><name><surname>Baral</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>T</given-names></name><name><surname>Gerstman</surname><given-names>B</given-names></name><name><surname>Chapagain</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Significance of the RBD mutations in the SARS-cov-2 omicron: from spike opening to antibody escape and cell attachment</article-title><source>Physical Chemistry Chemical Physics</source><volume>24</volume><fpage>9123</fpage><lpage>9129</lpage><pub-id pub-id-type="doi">10.1039/d2cp00169a</pub-id><pub-id pub-id-type="pmid">35395667</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Schaub</surname><given-names>JM</given-names></name><name><surname>DiVenere</surname><given-names>AM</given-names></name><name><surname>Kuo</surname><given-names>HC</given-names></name><name><surname>Javanmardi</surname><given-names>K</given-names></name><name><surname>Le</surname><given-names>KC</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>AG</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chou</surname><given-names>CW</given-names></name><name><surname>Byrne</surname><given-names>PO</given-names></name><name><surname>Hjorth</surname><given-names>CK</given-names></name><name><surname>Johnson</surname><given-names>NV</given-names></name><name><surname>Ludes-Meyers</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>AW</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Amengor</surname><given-names>D</given-names></name><name><surname>Lavinder</surname><given-names>JJ</given-names></name><name><surname>Ippolito</surname><given-names>GC</given-names></name><name><surname>Maynard</surname><given-names>JA</given-names></name><name><surname>Finkelstein</surname><given-names>IJ</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure-Based design of prefusion-stabilized SARS-cov-2 spikes</article-title><source>Science</source><volume>369</volume><fpage>1501</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1126/science.abd0826</pub-id><pub-id pub-id-type="pmid">32703906</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Werner</surname><given-names>AP</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Stevens</surname><given-names>LJ</given-names></name><name><surname>Falconer</surname><given-names>E</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Chou</surname><given-names>CW</given-names></name><name><surname>Abiona</surname><given-names>OM</given-names></name><name><surname>West</surname><given-names>A</given-names></name><name><surname>Westendorf</surname><given-names>K</given-names></name><name><surname>Muthuraman</surname><given-names>K</given-names></name><name><surname>Fritch</surname><given-names>EJ</given-names></name><name><surname>Dinnon</surname><given-names>KH</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Denison</surname><given-names>MR</given-names></name><name><surname>Chappell</surname><given-names>JD</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Stabilized coronavirus spike stem elicits a broadly protective antibody</article-title><source>Cell Reports</source><volume>37</volume><elocation-id>109929</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109929</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Kiso</surname><given-names>M</given-names></name><name><surname>Yamayoshi</surname><given-names>S</given-names></name><name><surname>Uraki</surname><given-names>R</given-names></name><name><surname>Fukushi</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Sakai-Tagawa</surname><given-names>Y</given-names></name><name><surname>Iwatsuki-Horimoto</surname><given-names>K</given-names></name><name><surname>Halfmann</surname><given-names>PJ</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB</article-title><source>The New England Journal of Medicine</source><volume>388</volume><fpage>89</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2214302</pub-id><pub-id pub-id-type="pmid">36476720</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Impagliazzo</surname><given-names>A</given-names></name><name><surname>Milder</surname><given-names>F</given-names></name><name><surname>Kuipers</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>MV</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Hoffman</surname><given-names>RMB</given-names></name><name><surname>van Meersbergen</surname><given-names>R</given-names></name><name><surname>Huizingh</surname><given-names>J</given-names></name><name><surname>Wanningen</surname><given-names>P</given-names></name><name><surname>Verspuij</surname><given-names>J</given-names></name><name><surname>de Man</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Apetri</surname><given-names>A</given-names></name><name><surname>Kükrer</surname><given-names>B</given-names></name><name><surname>Sneekes-Vriese</surname><given-names>E</given-names></name><name><surname>Tomkiewicz</surname><given-names>D</given-names></name><name><surname>Laursen</surname><given-names>NS</given-names></name><name><surname>Lee</surname><given-names>PS</given-names></name><name><surname>Zakrzewska</surname><given-names>A</given-names></name><name><surname>Dekking</surname><given-names>L</given-names></name><name><surname>Tolboom</surname><given-names>J</given-names></name><name><surname>Tettero</surname><given-names>L</given-names></name><name><surname>van Meerten</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Koudstaal</surname><given-names>W</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Meijberg</surname><given-names>W</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Radošević</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen</article-title><source>Science</source><volume>349</volume><fpage>1301</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1126/science.aac7263</pub-id><pub-id pub-id-type="pmid">26303961</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchdoerfer</surname><given-names>RN</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Pallesen</surname><given-names>J</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Turner</surname><given-names>HL</given-names></name><name><surname>Cottrell</surname><given-names>CA</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>15701</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-34171-7</pub-id><pub-id pub-id-type="pmid">30356097</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B</given-names></name><name><surname>Fischer</surname><given-names>WM</given-names></name><name><surname>Gnanakaran</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Theiler</surname><given-names>J</given-names></name><name><surname>Abfalterer</surname><given-names>W</given-names></name><name><surname>Hengartner</surname><given-names>N</given-names></name><name><surname>Giorgi</surname><given-names>EE</given-names></name><name><surname>Bhattacharya</surname><given-names>T</given-names></name><name><surname>Foley</surname><given-names>B</given-names></name><name><surname>Hastie</surname><given-names>KM</given-names></name><name><surname>Parker</surname><given-names>MD</given-names></name><name><surname>Partridge</surname><given-names>DG</given-names></name><name><surname>Evans</surname><given-names>CM</given-names></name><name><surname>Freeman</surname><given-names>TM</given-names></name><name><surname>de Silva</surname><given-names>TI</given-names></name><name><surname>McDanal</surname><given-names>C</given-names></name><name><surname>Perez</surname><given-names>LG</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Moon-Walker</surname><given-names>A</given-names></name><name><surname>Whelan</surname><given-names>SP</given-names></name><name><surname>LaBranche</surname><given-names>CC</given-names></name><name><surname>Saphire</surname><given-names>EO</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><collab>Sheffield COVID-19 Genomics Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Tracking changes in SARS-cov-2 spike: evidence that D614G increases infectivity of the COVID-19 virus</article-title><source>Cell</source><volume>182</volume><fpage>812</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.043</pub-id><pub-id pub-id-type="pmid">32697968</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebber</surname><given-names>A</given-names></name><name><surname>Bornhauser</surname><given-names>S</given-names></name><name><surname>Burmester</surname><given-names>J</given-names></name><name><surname>Honegger</surname><given-names>A</given-names></name><name><surname>Willuda</surname><given-names>J</given-names></name><name><surname>Bosshard</surname><given-names>HR</given-names></name><name><surname>Plückthun</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system</article-title><source>Journal of Immunological Methods</source><volume>201</volume><fpage>35</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/s0022-1759(96)00208-6</pub-id><pub-id pub-id-type="pmid">9032408</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladner</surname><given-names>JT</given-names></name><name><surname>Henson</surname><given-names>SN</given-names></name><name><surname>Boyle</surname><given-names>AS</given-names></name><name><surname>Engelbrektson</surname><given-names>AL</given-names></name><name><surname>Fink</surname><given-names>ZW</given-names></name><name><surname>Rahee</surname><given-names>F</given-names></name><name><surname>D’ambrozio</surname><given-names>J</given-names></name><name><surname>Schaecher</surname><given-names>KE</given-names></name><name><surname>Stone</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Dadwal</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Cieplak</surname><given-names>P</given-names></name><name><surname>Bjørås</surname><given-names>M</given-names></name><name><surname>Fenstad</surname><given-names>MH</given-names></name><name><surname>Nordbø</surname><given-names>SA</given-names></name><name><surname>Kainov</surname><given-names>DE</given-names></name><name><surname>Muranaka</surname><given-names>N</given-names></name><name><surname>Chee</surname><given-names>MS</given-names></name><name><surname>Shiryaev</surname><given-names>SA</given-names></name><name><surname>Altin</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Epitope-resolved profiling of the SARS-cov-2 antibody response identifies cross-reactivity with endemic human coronaviruses</article-title><source>Cell Reports. Medicine</source><volume>2</volume><elocation-id>100189</elocation-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100189</pub-id><pub-id pub-id-type="pmid">33495758</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Prévost</surname><given-names>J</given-names></name><name><surname>Ullah</surname><given-names>I</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>SY</given-names></name><name><surname>Tauzin</surname><given-names>A</given-names></name><name><surname>Gasser</surname><given-names>R</given-names></name><name><surname>Vézina</surname><given-names>D</given-names></name><name><surname>Anand</surname><given-names>SP</given-names></name><name><surname>Goyette</surname><given-names>G</given-names></name><name><surname>Chaterjee</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Tolbert</surname><given-names>WD</given-names></name><name><surname>Grunst</surname><given-names>MW</given-names></name><name><surname>Bo</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Richard</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>RK</given-names></name><name><surname>Esser</surname><given-names>L</given-names></name><name><surname>Zeher</surname><given-names>A</given-names></name><name><surname>Côté</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>D</given-names></name><name><surname>Uchil</surname><given-names>PD</given-names></name><name><surname>Pazgier</surname><given-names>M</given-names></name><name><surname>Finzi</surname><given-names>A</given-names></name><name><surname>Mothes</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural basis and mode of action for two broadly neutralizing antibodies against SARS-cov-2 emerging variants of concern</article-title><source>Cell Reports</source><volume>38</volume><elocation-id>110210</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110210</pub-id><pub-id pub-id-type="pmid">34971573</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Bangaru</surname><given-names>S</given-names></name><name><surname>Torres</surname><given-names>JL</given-names></name><name><surname>Caniels</surname><given-names>TG</given-names></name><name><surname>van Schooten</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>CCD</given-names></name><name><surname>Brouwer</surname><given-names>PJM</given-names></name><name><surname>van Gils</surname><given-names>MJ</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cross-neutralization of a SARS-cov-2 antibody to a functionally conserved site is mediated by avidity</article-title><source>Immunity</source><volume>53</volume><fpage>1272</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.10.023</pub-id><pub-id pub-id-type="pmid">33242394</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>JS</given-names></name><name><surname>Jerak</surname><given-names>J</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>McCallum</surname><given-names>M</given-names></name><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Cassotta</surname><given-names>A</given-names></name><name><surname>Foglierini</surname><given-names>M</given-names></name><name><surname>Mele</surname><given-names>F</given-names></name><name><surname>Abdelnabi</surname><given-names>R</given-names></name><name><surname>Weynand</surname><given-names>B</given-names></name><name><surname>Noack</surname><given-names>J</given-names></name><name><surname>Montiel-Ruiz</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Benigni</surname><given-names>F</given-names></name><name><surname>Sprugasci</surname><given-names>N</given-names></name><name><surname>Joshi</surname><given-names>A</given-names></name><name><surname>Bowen</surname><given-names>JE</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Rexhepaj</surname><given-names>M</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Jarrossay</surname><given-names>D</given-names></name><name><surname>Morone</surname><given-names>D</given-names></name><name><surname>Paparoditis</surname><given-names>P</given-names></name><name><surname>Garzoni</surname><given-names>C</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Ceschi</surname><given-names>A</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Purcell</surname><given-names>LA</given-names></name><name><surname>Snell</surname><given-names>G</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ACE2-binding exposes the SARS-cov-2 fusion peptide to broadly neutralizing coronavirus antibodies</article-title><source>Science</source><volume>377</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1126/science.abq2679</pub-id><pub-id pub-id-type="pmid">35857703</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motulsky</surname><given-names>HJ</given-names></name><name><surname>Brown</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Detecting outliers when fitting data with nonlinear regression-a new method based on robust nonlinear regression and the false discovery rate</article-title><source>BMC Bioinformatics</source><volume>7</volume><elocation-id>123</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-7-123</pub-id><pub-id pub-id-type="pmid">16526949</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>KW</given-names></name><name><surname>Faulkner</surname><given-names>N</given-names></name><name><surname>Cornish</surname><given-names>GH</given-names></name><name><surname>Rosa</surname><given-names>A</given-names></name><name><surname>Harvey</surname><given-names>R</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Ulferts</surname><given-names>R</given-names></name><name><surname>Earl</surname><given-names>C</given-names></name><name><surname>Wrobel</surname><given-names>AG</given-names></name><name><surname>Benton</surname><given-names>DJ</given-names></name><name><surname>Roustan</surname><given-names>C</given-names></name><name><surname>Bolland</surname><given-names>W</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Agua-Doce</surname><given-names>A</given-names></name><name><surname>Hobson</surname><given-names>P</given-names></name><name><surname>Heaney</surname><given-names>J</given-names></name><name><surname>Rickman</surname><given-names>H</given-names></name><name><surname>Paraskevopoulou</surname><given-names>S</given-names></name><name><surname>Houlihan</surname><given-names>CF</given-names></name><name><surname>Thomson</surname><given-names>K</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Shin</surname><given-names>GY</given-names></name><name><surname>Spyer</surname><given-names>MJ</given-names></name><name><surname>Joshi</surname><given-names>D</given-names></name><name><surname>O’Reilly</surname><given-names>N</given-names></name><name><surname>Walker</surname><given-names>PA</given-names></name><name><surname>Kjaer</surname><given-names>S</given-names></name><name><surname>Riddell</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Jebson</surname><given-names>BR</given-names></name><name><surname>Wilkinson</surname><given-names>M</given-names></name><name><surname>Marshall</surname><given-names>LR</given-names></name><name><surname>Rosser</surname><given-names>EC</given-names></name><name><surname>Radziszewska</surname><given-names>A</given-names></name><name><surname>Peckham</surname><given-names>H</given-names></name><name><surname>Ciurtin</surname><given-names>C</given-names></name><name><surname>Wedderburn</surname><given-names>LR</given-names></name><name><surname>Beale</surname><given-names>R</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><name><surname>Gandhi</surname><given-names>S</given-names></name><name><surname>Stockinger</surname><given-names>B</given-names></name><name><surname>McCauley</surname><given-names>J</given-names></name><name><surname>Gamblin</surname><given-names>SJ</given-names></name><name><surname>McCoy</surname><given-names>LE</given-names></name><name><surname>Cherepanov</surname><given-names>P</given-names></name><name><surname>Nastouli</surname><given-names>E</given-names></name><name><surname>Kassiotis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Preexisting and de novo humoral immunity to SARS-cov-2 in humans</article-title><source>Science</source><volume>370</volume><fpage>1339</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1126/science.abe1107</pub-id><pub-id pub-id-type="pmid">33159009</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>AW</given-names></name><name><surname>Wagner</surname><given-names>EK</given-names></name><name><surname>Laber</surname><given-names>JR</given-names></name><name><surname>Goodfield</surname><given-names>LL</given-names></name><name><surname>Smallridge</surname><given-names>WE</given-names></name><name><surname>Harvill</surname><given-names>ET</given-names></name><name><surname>Papin</surname><given-names>JF</given-names></name><name><surname>Wolf</surname><given-names>RF</given-names></name><name><surname>Padlan</surname><given-names>EA</given-names></name><name><surname>Bristol</surname><given-names>A</given-names></name><name><surname>Kaleko</surname><given-names>M</given-names></name><name><surname>Maynard</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>316ra195</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aad0966</pub-id><pub-id pub-id-type="pmid">26631634</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>AW</given-names></name><name><surname>Le</surname><given-names>KC</given-names></name><name><surname>Maynard</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of high affinity HER2 binding antibodies using CHO Fab surface display</article-title><source>Protein Engineering, Design &amp; Selection</source><volume>31</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1093/protein/gzy004</pub-id><pub-id pub-id-type="pmid">29566240</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallesen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Kirchdoerfer</surname><given-names>RN</given-names></name><name><surname>Turner</surname><given-names>HL</given-names></name><name><surname>Cottrell</surname><given-names>CA</given-names></name><name><surname>Becker</surname><given-names>MM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>WP</given-names></name><name><surname>Andres</surname><given-names>EL</given-names></name><name><surname>Kettenbach</surname><given-names>AN</given-names></name><name><surname>Denison</surname><given-names>MR</given-names></name><name><surname>Chappell</surname><given-names>JD</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Immunogenicity and structures of a rationally designed prefusion MERS-cov spike antigen</article-title><source>PNAS</source><volume>114</volume><fpage>E7348</fpage><lpage>E7357</lpage><pub-id pub-id-type="doi">10.1073/pnas.1707304114</pub-id><pub-id pub-id-type="pmid">28807998</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>UCSF chimerax: structure visualization for researchers, educators, and developers</article-title><source>Protein Science</source><volume>30</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/pro.3943</pub-id><pub-id pub-id-type="pmid">32881101</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piepenbrink</surname><given-names>MS</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name><name><surname>Deshpande</surname><given-names>A</given-names></name><name><surname>Loos</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Basu</surname><given-names>M</given-names></name><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Khalil</surname><given-names>AM</given-names></name><name><surname>Chauvin</surname><given-names>D</given-names></name><name><surname>Woo</surname><given-names>J</given-names></name><name><surname>Lovalenti</surname><given-names>P</given-names></name><name><surname>Erdmann</surname><given-names>NB</given-names></name><name><surname>Goepfert</surname><given-names>PA</given-names></name><name><surname>Truong</surname><given-names>VL</given-names></name><name><surname>Bowen</surname><given-names>RA</given-names></name><name><surname>Walter</surname><given-names>MR</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L</given-names></name><name><surname>Kobie</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a spike S2 domain-specific human neutralizing monoclonal antibody</article-title><source>PLOS Pathogens</source><volume>18</volume><elocation-id>e1010691</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010691</pub-id><pub-id pub-id-type="pmid">35862475</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>Y-J</given-names></name><name><surname>Beltramello</surname><given-names>M</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Jaconi</surname><given-names>S</given-names></name><name><surname>Culap</surname><given-names>K</given-names></name><name><surname>Zatta</surname><given-names>F</given-names></name><name><surname>De Marco</surname><given-names>A</given-names></name><name><surname>Peter</surname><given-names>A</given-names></name><name><surname>Guarino</surname><given-names>B</given-names></name><name><surname>Spreafico</surname><given-names>R</given-names></name><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Case</surname><given-names>JB</given-names></name><name><surname>Chen</surname><given-names>RE</given-names></name><name><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name><surname>Snell</surname><given-names>G</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Fink</surname><given-names>K</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cross-Neutralization of SARS-cov-2 by a human monoclonal SARS-CoV antibody</article-title><source>Nature</source><volume>583</volume><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2349-y</pub-id><pub-id pub-id-type="pmid">32422645</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D</given-names></name><name><surname>Sauer</surname><given-names>MM</given-names></name><name><surname>Czudnochowski</surname><given-names>N</given-names></name><name><surname>Low</surname><given-names>JS</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Housley</surname><given-names>MP</given-names></name><name><surname>Noack</surname><given-names>J</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Bowen</surname><given-names>JE</given-names></name><name><surname>Guarino</surname><given-names>B</given-names></name><name><surname>Rosen</surname><given-names>LE</given-names></name><name><surname>di Iulio</surname><given-names>J</given-names></name><name><surname>Jerak</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>H</given-names></name><name><surname>Islam</surname><given-names>S</given-names></name><name><surname>Jaconi</surname><given-names>S</given-names></name><name><surname>Sprugasci</surname><given-names>N</given-names></name><name><surname>Culap</surname><given-names>K</given-names></name><name><surname>Abdelnabi</surname><given-names>R</given-names></name><name><surname>Foo</surname><given-names>C</given-names></name><name><surname>Coelmont</surname><given-names>L</given-names></name><name><surname>Bartha</surname><given-names>I</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Silacci-Fregni</surname><given-names>C</given-names></name><name><surname>Bassi</surname><given-names>J</given-names></name><name><surname>Marzi</surname><given-names>R</given-names></name><name><surname>Vetti</surname><given-names>E</given-names></name><name><surname>Cassotta</surname><given-names>A</given-names></name><name><surname>Ceschi</surname><given-names>A</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Cippà</surname><given-names>PE</given-names></name><name><surname>Giannini</surname><given-names>O</given-names></name><name><surname>Ceruti</surname><given-names>S</given-names></name><name><surname>Garzoni</surname><given-names>C</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name><name><surname>Benigni</surname><given-names>F</given-names></name><name><surname>Cameroni</surname><given-names>E</given-names></name><name><surname>Piccoli</surname><given-names>L</given-names></name><name><surname>Pizzuto</surname><given-names>MS</given-names></name><name><surname>Smithey</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>D</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Lempp</surname><given-names>FA</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Snell</surname><given-names>G</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Beltramello</surname><given-names>M</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Broad betacoronavirus neutralization by a stem helix-specific human antibody</article-title><source>Science</source><volume>373</volume><fpage>1109</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1126/science.abj3321</pub-id><pub-id pub-id-type="pmid">34344823</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name><name><surname>Fleet</surname><given-names>DJ</given-names></name><name><surname>Brubaker</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raybould</surname><given-names>MIJ</given-names></name><name><surname>Kovaltsuk</surname><given-names>A</given-names></name><name><surname>Marks</surname><given-names>C</given-names></name><name><surname>Deane</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CoV-abdab: the coronavirus antibody database</article-title><source>Bioinformatics</source><volume>37</volume><fpage>734</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa739</pub-id><pub-id pub-id-type="pmid">32805021</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>TF</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Beutler</surname><given-names>N</given-names></name><name><surname>Burns</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>WT</given-names></name><name><surname>Limbo</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Woehl</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Abbott</surname><given-names>RK</given-names></name><name><surname>Callaghan</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Hurtado</surname><given-names>J</given-names></name><name><surname>Parren</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Ramirez</surname><given-names>S</given-names></name><name><surname>Ricketts</surname><given-names>J</given-names></name><name><surname>Ricciardi</surname><given-names>MJ</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name><name><surname>Teijaro</surname><given-names>JR</given-names></name><name><surname>Voss</surname><given-names>JE</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Andrabi</surname><given-names>R</given-names></name><name><surname>Briney</surname><given-names>B</given-names></name><name><surname>Landais</surname><given-names>E</given-names></name><name><surname>Sok</surname><given-names>D</given-names></name><name><surname>Jardine</surname><given-names>JG</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Isolation of potent SARS-cov-2 neutralizing antibodies and protection from disease in a small animal model</article-title><source>Science</source><volume>369</volume><fpage>956</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1126/science.abc7520</pub-id><pub-id pub-id-type="pmid">32540903</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>MM</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Park</surname><given-names>Y-J</given-names></name><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Homad</surname><given-names>L</given-names></name><name><surname>Acton</surname><given-names>OJ</given-names></name><name><surname>Bowen</surname><given-names>JE</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>de van der Schueren</surname><given-names>W</given-names></name><name><surname>Quispe</surname><given-names>J</given-names></name><name><surname>Hoffstrom</surname><given-names>BG</given-names></name><name><surname>Bosch</surname><given-names>B-J</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structural basis for broad coronavirus neutralization</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>28</volume><fpage>478</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/s41594-021-00596-4</pub-id><pub-id pub-id-type="pmid">33981021</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Garman</surname><given-names>L</given-names></name><name><surname>Wrammert</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>NY</given-names></name><name><surname>Capra</surname><given-names>JD</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen</article-title><source>Nature Protocols</source><volume>4</volume><fpage>372</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.3</pub-id><pub-id pub-id-type="pmid">19247287</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starr</surname><given-names>TN</given-names></name><name><surname>Greaney</surname><given-names>AJ</given-names></name><name><surname>Addetia</surname><given-names>A</given-names></name><name><surname>Hannon</surname><given-names>WW</given-names></name><name><surname>Choudhary</surname><given-names>MC</given-names></name><name><surname>Dingens</surname><given-names>AS</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><name><surname>Bloom</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prospective mapping of viral mutations that escape antibodies used to treat COVID-19</article-title><source>Science</source><volume>371</volume><fpage>850</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1126/science.abf9302</pub-id><pub-id pub-id-type="pmid">33495308</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Deng</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Ling</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-cov-2</article-title><source>Nature Microbiology</source><volume>7</volume><fpage>1063</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01155-3</pub-id><pub-id pub-id-type="pmid">35773398</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ter Meulen</surname><given-names>J</given-names></name><name><surname>van den Brink</surname><given-names>EN</given-names></name><name><surname>Poon</surname><given-names>LLM</given-names></name><name><surname>Marissen</surname><given-names>WE</given-names></name><name><surname>Leung</surname><given-names>CSW</given-names></name><name><surname>Cox</surname><given-names>F</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Bakker</surname><given-names>AQ</given-names></name><name><surname>Bogaards</surname><given-names>JA</given-names></name><name><surname>van Deventer</surname><given-names>E</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name><name><surname>Chow</surname><given-names>VT</given-names></name><name><surname>de Kruif</surname><given-names>J</given-names></name><name><surname>Peiris</surname><given-names>JSM</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants</article-title><source>PLOS Medicine</source><volume>3</volume><elocation-id>e237</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0030237</pub-id><pub-id pub-id-type="pmid">16796401</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullah</surname><given-names>I</given-names></name><name><surname>Prévost</surname><given-names>J</given-names></name><name><surname>Ladinsky</surname><given-names>MS</given-names></name><name><surname>Stone</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Anand</surname><given-names>SP</given-names></name><name><surname>Beaudoin-Bussières</surname><given-names>G</given-names></name><name><surname>Symmes</surname><given-names>K</given-names></name><name><surname>Benlarbi</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Gasser</surname><given-names>R</given-names></name><name><surname>Fink</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Tauzin</surname><given-names>A</given-names></name><name><surname>Goyette</surname><given-names>G</given-names></name><name><surname>Bourassa</surname><given-names>C</given-names></name><name><surname>Medjahed</surname><given-names>H</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>K</given-names></name><name><surname>Wilen</surname><given-names>CB</given-names></name><name><surname>Dekaban</surname><given-names>GA</given-names></name><name><surname>Dikeakos</surname><given-names>JD</given-names></name><name><surname>Bruce</surname><given-names>EA</given-names></name><name><surname>Kaufmann</surname><given-names>DE</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Richard</surname><given-names>J</given-names></name><name><surname>Pazgier</surname><given-names>M</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Mothes</surname><given-names>W</given-names></name><name><surname>Finzi</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Uchil</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Live imaging of SARS-cov-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy</article-title><source>Immunity</source><volume>54</volume><fpage>2143</fpage><lpage>2158</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.08.015</pub-id><pub-id pub-id-type="pmid">34453881</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>VanBlargan</surname><given-names>LA</given-names></name><name><surname>Errico</surname><given-names>JM</given-names></name><name><surname>Halfmann</surname><given-names>PJ</given-names></name><name><surname>Zost</surname><given-names>SJ</given-names></name><name><surname>Crowe</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Purcell</surname><given-names>LA</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Fremont</surname><given-names>DH</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>An infectious SARS-cov-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies</article-title><source>Nature Medicine</source><volume>28</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01678-y</pub-id><pub-id pub-id-type="pmid">35046573</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname><given-names>WN</given-names></name><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>Johnson</surname><given-names>NV</given-names></name><name><surname>Delidakis</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Javanmardi</surname><given-names>K</given-names></name><name><surname>Horton</surname><given-names>AP</given-names></name><name><surname>Bartzoka</surname><given-names>F</given-names></name><name><surname>Paresi</surname><given-names>CJ</given-names></name><name><surname>Tanno</surname><given-names>Y</given-names></name><name><surname>Chou</surname><given-names>C-W</given-names></name><name><surname>Abbasi</surname><given-names>SA</given-names></name><name><surname>Pickens</surname><given-names>W</given-names></name><name><surname>George</surname><given-names>K</given-names></name><name><surname>Boutz</surname><given-names>DR</given-names></name><name><surname>Towers</surname><given-names>DM</given-names></name><name><surname>McDaniel</surname><given-names>JR</given-names></name><name><surname>Billick</surname><given-names>D</given-names></name><name><surname>Goike</surname><given-names>J</given-names></name><name><surname>Rowe</surname><given-names>L</given-names></name><name><surname>Batra</surname><given-names>D</given-names></name><name><surname>Pohl</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Gangappa</surname><given-names>S</given-names></name><name><surname>Sambhara</surname><given-names>S</given-names></name><name><surname>Gadush</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Person</surname><given-names>MD</given-names></name><name><surname>Iverson</surname><given-names>BL</given-names></name><name><surname>Gollihar</surname><given-names>JD</given-names></name><name><surname>Dye</surname><given-names>JM</given-names></name><name><surname>Herbert</surname><given-names>AS</given-names></name><name><surname>Finkelstein</surname><given-names>IJ</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name><name><surname>Lavinder</surname><given-names>JJ</given-names></name><name><surname>Ippolito</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prevalent, protective, and convergent IgG recognition of SARS-cov-2 non-RBD spike epitopes</article-title><source>Science</source><volume>372</volume><fpage>1108</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1126/science.abg5268</pub-id><pub-id pub-id-type="pmid">33947773</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure, function, and antigenicity of the SARS-cov-2 spike glycoprotein</article-title><source>Cell</source><volume>181</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>DeKosky</surname><given-names>BJ</given-names></name><name><surname>Timm</surname><given-names>MR</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Normandin</surname><given-names>E</given-names></name><name><surname>Misasi</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>McDaniel</surname><given-names>JR</given-names></name><name><surname>Delidakis</surname><given-names>G</given-names></name><name><surname>Leigh</surname><given-names>KE</given-names></name><name><surname>Niezold</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>CW</given-names></name><name><surname>Viox</surname><given-names>EG</given-names></name><name><surname>Fahad</surname><given-names>A</given-names></name><name><surname>Cagigi</surname><given-names>A</given-names></name><name><surname>Ploquin</surname><given-names>A</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>ES</given-names></name><name><surname>Kong</surname><given-names>W-P</given-names></name><name><surname>Voss</surname><given-names>WN</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Ambrozak</surname><given-names>DR</given-names></name><name><surname>Henry</surname><given-names>AR</given-names></name><name><surname>Laboune</surname><given-names>F</given-names></name><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Sullivan</surname><given-names>NJ</given-names></name><name><surname>Ellington</surname><given-names>AD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Functional interrogation and mining of natively paired human VH:VL antibody repertoires</article-title><source>Nature Biotechnology</source><volume>36</volume><fpage>152</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/nbt.4052</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>van Haperen</surname><given-names>R</given-names></name><name><surname>Gutiérrez-Álvarez</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Okba</surname><given-names>NMA</given-names></name><name><surname>Albulescu</surname><given-names>I</given-names></name><name><surname>Widjaja</surname><given-names>I</given-names></name><name><surname>van Dieren</surname><given-names>B</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R</given-names></name><name><surname>Sola</surname><given-names>I</given-names></name><name><surname>Hurdiss</surname><given-names>DL</given-names></name><name><surname>Daramola</surname><given-names>O</given-names></name><name><surname>Grosveld</surname><given-names>F</given-names></name><name><surname>van Kuppeveld</surname><given-names>FJM</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>Enjuanes</surname><given-names>L</given-names></name><name><surname>Drabek</surname><given-names>D</given-names></name><name><surname>Bosch</surname><given-names>B-J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1715</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21968-w</pub-id><pub-id pub-id-type="pmid">33731724</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>DD</given-names></name><name><surname>Wales</surname><given-names>TE</given-names></name><name><surname>Engen</surname><given-names>JR</given-names></name><name><surname>Hotchko</surname><given-names>M</given-names></name><name><surname>Ten Eyck</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Identification and characterization of EX1 kinetics in H/D exchange mass spectrometry by peak width analysis</article-title><source>Journal of the American Society for Mass Spectrometry</source><volume>17</volume><fpage>1498</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1016/j.jasms.2006.05.014</pub-id><pub-id pub-id-type="pmid">16875839</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wentz</surname><given-names>AE</given-names></name><name><surname>Shusta</surname><given-names>EV</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A novel high-throughput screen reveals yeast genes that increase secretion of heterologous proteins</article-title><source>Applied and Environmental Microbiology</source><volume>73</volume><fpage>1189</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1128/AEM.02427-06</pub-id><pub-id pub-id-type="pmid">17189442</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>De Vlieger</surname><given-names>D</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Torres</surname><given-names>GM</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Van Breedam</surname><given-names>W</given-names></name><name><surname>Roose</surname><given-names>K</given-names></name><name><surname>van Schie</surname><given-names>L</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Callewaert</surname><given-names>N</given-names></name><name><surname>Schepens</surname><given-names>B</given-names></name><name><surname>Saelens</surname><given-names>X</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><collab>VIB-CMB COVID-19 Response Team</collab></person-group><year iso-8601-date="2020">2020a</year><article-title>Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies</article-title><source>Cell</source><volume>181</volume><fpage>1004</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.031</pub-id><pub-id pub-id-type="pmid">32375025</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name><name><surname>Goldsmith</surname><given-names>JA</given-names></name><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Abiona</surname><given-names>O</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Cryo-em structure of the 2019-ncov spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>K</given-names></name><name><surname>Ciazynska</surname><given-names>KA</given-names></name><name><surname>Hosmillo</surname><given-names>M</given-names></name><name><surname>Carter</surname><given-names>AP</given-names></name><name><surname>Ebrahimi</surname><given-names>S</given-names></name><name><surname>Ke</surname><given-names>Z</given-names></name><name><surname>Scheres</surname><given-names>SHW</given-names></name><name><surname>Bergamaschi</surname><given-names>L</given-names></name><name><surname>Grice</surname><given-names>GL</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Collaboration</surname><given-names>CNCB</given-names></name><name><surname>Nathan</surname><given-names>JA</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>LC</given-names></name><name><surname>Baxendale</surname><given-names>HE</given-names></name><name><surname>Goodfellow</surname><given-names>I</given-names></name><name><surname>Doffinger</surname><given-names>R</given-names></name><name><surname>Briggs</surname><given-names>JAG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A thermostable, closed SARS-cov-2 spike protein trimer</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>934</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0478-5</pub-id><pub-id pub-id-type="pmid">32737467</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>NC</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Recognition of the SARS-cov-2 receptor binding domain by neutralizing antibodies</article-title><source>Biochemical and Biophysical Research Communications</source><volume>538</volume><fpage>192</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.10.012</pub-id><pub-id pub-id-type="pmid">33069360</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>D’Arcy</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HD-explosion: visualization of hydrogen-deuterium exchange data as chiclet and volcano plots with statistical filtering</article-title><source>Bioinformatics</source><volume>37</volume><fpage>1926</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa892</pub-id><pub-id pub-id-type="pmid">33079991</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Tsybovsky</surname><given-names>Y</given-names></name><name><surname>Gorman</surname><given-names>J</given-names></name><name><surname>Rapp</surname><given-names>M</given-names></name><name><surname>Cerutti</surname><given-names>G</given-names></name><name><surname>Chuang</surname><given-names>G-Y</given-names></name><name><surname>Katsamba</surname><given-names>PS</given-names></name><name><surname>Sampson</surname><given-names>JM</given-names></name><name><surname>Schön</surname><given-names>A</given-names></name><name><surname>Bimela</surname><given-names>J</given-names></name><name><surname>Boyington</surname><given-names>JC</given-names></name><name><surname>Nazzari</surname><given-names>A</given-names></name><name><surname>Olia</surname><given-names>AS</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Sastry</surname><given-names>M</given-names></name><name><surname>Stephens</surname><given-names>T</given-names></name><name><surname>Stuckey</surname><given-names>J</given-names></name><name><surname>Teng</surname><given-names>I-T</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Friesner</surname><given-names>RA</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-Em structures of SARS-cov-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains</article-title><source>Cell Host &amp; Microbe</source><volume>28</volume><fpage>867</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.11.004</pub-id><pub-id pub-id-type="pmid">33271067</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Beutler</surname><given-names>N</given-names></name><name><surname>Shaabani</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>WT</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Callaghan</surname><given-names>S</given-names></name><name><surname>Yong</surname><given-names>P</given-names></name><name><surname>Anzanello</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Ricketts</surname><given-names>J</given-names></name><name><surname>Parren</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name><name><surname>Teijaro</surname><given-names>JR</given-names></name><name><surname>Rogers</surname><given-names>TF</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Andrabi</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-cov-2 infection</article-title><source>Science Translational Medicine</source><volume>14</volume><elocation-id>eabi9215</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abi9215</pub-id><pub-id pub-id-type="pmid">35133175</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>MI</given-names></name><name><surname>Porter</surname><given-names>JR</given-names></name><name><surname>Ward</surname><given-names>MD</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Vithani</surname><given-names>N</given-names></name><name><surname>Meller</surname><given-names>A</given-names></name><name><surname>Mallimadugula</surname><given-names>UL</given-names></name><name><surname>Kuhn</surname><given-names>CE</given-names></name><name><surname>Borowsky</surname><given-names>JH</given-names></name><name><surname>Wiewiora</surname><given-names>RP</given-names></name><name><surname>Hurley</surname><given-names>MFD</given-names></name><name><surname>Harbison</surname><given-names>AM</given-names></name><name><surname>Fogarty</surname><given-names>CA</given-names></name><name><surname>Coffland</surname><given-names>JE</given-names></name><name><surname>Fadda</surname><given-names>E</given-names></name><name><surname>Voelz</surname><given-names>VA</given-names></name><name><surname>Chodera</surname><given-names>JD</given-names></name><name><surname>Bowman</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-cov-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome</article-title><source>Nature Chemistry</source><volume>13</volume><fpage>651</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/s41557-021-00707-0</pub-id><pub-id pub-id-type="pmid">34031561</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83710.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goo</surname><given-names>Leslie</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.01.31.428824" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.01.31.428824"/></front-stub><body><p>This study presents valuable findings on the isolation of an antibody that recognizes a novel, highly conserved SARS-CoV-2 Spike (S) epitope, adding to the growing repertoire of anti-S antibodies cross-reactive against human and zoonotic coronaviruses. The authors provide solid evidence supporting their claims, although the proposed antiviral mechanism of the newly described antibody requires further validation, and in vivo effectiveness remains to be determined. The work will be of interest to biologists working to develop pan-coronavirus vaccines and therapies.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83710.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Goo</surname><given-names>Leslie</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.01.31.428824">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.31.428824v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Evaluation of the highly conserved S2 hairpin hinge as a pan-coronavirus target&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Sara Sawyer (U. Colorado Boulder) as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The authors' claim that the S2 hinge epitope is of interest for pan-coronavirus strategies is too speculative based on the data presented. This epitope was identified via the characterization of an antibody (3A3) isolated following immunization with a MERS S2 domain in a mouse model. Further, the fact that 3A3 binds to 2P-stabilized, but not native spike suggests that 3A3-like antibodies are unlikely to arise from natural infection. Thus, the authors should focus their key message on the discovery of a new S2 epitope and tone down the language regarding its broader implications for pan-coronavirus strategies throughout the manuscript. To more directly support the latter, the authors would need to provide evidence that 3A3-like antibodies can be isolated from human donors and/or that access to the hinge epitope can be enhanced via synergy with ACE2-mimicking antibodies or antibodies that promote S1 shedding that has been previously described.</p><p>2) Another main claim of the study is that antibody targeting the hinge is weakly neutralizing but mediates Fc-effector functions in vitro. Experiments using engineered constructs that modulate effector function (e.g., DLE (+) or LALA (-)) would more directly support this claim.</p><p>3) The chosen experimental conditions for HDXMS seemingly do not take into account the role of temperature on spike intrinsic ensemble heterogeneity (prefusion vs expanded) as previously described (PMID: 35236990). The authors must at least clarify why their HDXMS experimental conditions included thawing of frozen samples (-80 C) and brief (10 min) equilibration at 25 C instead of prolonged 37 C treatment. which favors the relevant prefusion conformation according to the above published study. Is the conformational heterogeneity in biological replicates equivalent following short incubation at 25 C and longer incubation at 37 C?</p><p>4) The S2 hinge epitope is partially occluded by the S1 domain and access is contingent on RBD up-down conformational switching. The authors should better integrate findings from the various approaches described (HDX-MS, cryo-EM, antibody engineering) to help readers understand possible mechanisms for how antibodies bind this epitope.</p><p>5) A discussion of the allosteric effects of 3A3 binding to the spike trimer, particularly with regards to cooperativity in antibody binding is warranted. In this regard, the reader would also benefit from HDXMS spectral envelopes, at least for peptides within the epitope locus.</p><p>6) In Figure 1A, regions lacking HDX-M/S coverage are indicated in grey, which is too similar to regions with coverage but with low/no rate of exchange. Please distinguish regions with and without coverage more clearly.</p><p>7) In Figure 2F, please define dashed versus solid arrows.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1) Readers would benefit from HDXMS spectral envelopes in figures, at least for the epitope locus peptides.</p><p>2) Authors should describe the ensemble heterogeneity observed in HDXMS and the basis for not applying a 37 deg C treatment of samples prior to HDXMS mapping studies with 3A3.</p><p>3) The reader would benefit from better integration of structural, solution (HDXMS), and antibody engineering approaches in the manuscript. This would bring out a more definitive conclusion on the mechanism of targeting the hinge epitope.</p><p>4) The authors should address the lack of allostery observed and cooperativity of antibody binding.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>This manuscript describes work on targeting the conserved S2 hinge region, an underappreciated target that is similar to the flu stem region which universal antibodies target. Overall, this work is nicely carried out.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83710.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors' claim that the S2 hinge epitope is of interest for pan-coronavirus strategies is too speculative based on the data presented. This epitope was identified via the characterization of an antibody (3A3) isolated following immunization with a MERS S2 domain in a mouse model. Further, the fact that 3A3 binds to 2P-stabilized, but not native spike suggests that 3A3-like antibodies are unlikely to arise from natural infection. Thus, the authors should focus their key message on the discovery of a new S2 epitope and tone down the language regarding its broader implications for pan-coronavirus strategies throughout the manuscript. To more directly support the latter, the authors would need to provide evidence that 3A3-like antibodies can be isolated from human donors and/or that access to the hinge epitope can be enhanced via synergy with ACE2-mimicking antibodies or antibodies that promote S1 shedding that has been previously described.</p></disp-quote><p>As suggested, we have edited several parts of the manuscript to reduce the claims around the impact of this work on pan-coronavirus strategies:</p><p>Edited title to “Identification of a conserved epitope present on spike proteins from all highly pathogenic coronaviruses” to reduce the focus on pan-coronavirus strategies.</p><p>Deleted “that can guide future pan-coronavirus strategies.” in the abstract.</p><p>Revised “Evaluation of the S2 hinge epitope… will inform design of next-generation pan-coronavirus vaccines and related therapeutic strategies” to “… will inform our understanding of the role of S2 domain epitopes in antibody recognition.”</p><p>1<sup>st</sup> paragraph of Discussion section: Deleted as the focus was on S2 epitopes as pan-coronavirus targets.</p><p>Though we do not plan to isolate 3A3-like antibodies from human donors, there is evidence that these antibodies are elicited in infected humans via analysis of polyclonal responses in Claireaux <italic>et al.</italic> 2022. We also know of several studies on naturally occurring S2 hinge targeting antibodies from colleagues that are in preparation. Understanding the therapeutic role of this antibody class is relevant to the study of broadly-reactive S2 antibodies, even if that role is limited.</p><disp-quote content-type="editor-comment"><p>2) Another main claim of the study is that antibody targeting the hinge is weakly neutralizing but mediates Fc-effector functions in vitro. Experiments using engineered constructs that modulate effector function (e.g., DLE (+) or LALA (-)) would more directly support this claim.</p></disp-quote><p>We agree these are excellent controls to include, in addition to isotype controls already shown. In accordance with the <italic>eLife</italic> COVID research policy, we minimized our claims around Fc-effector functions elicited by RAY53 and stated that further experiments to confirm our preliminary findings are needed.</p><p>The existing description of the effector function experiments states “These results indicate that RAY53 binding is compatible with ADCP and ADCC,” which is already a very limited claim.</p><p>We also added in line 450 that S2 core-binding antibodies “require further validation” of their ability to recruit effector functions.</p><p>We appreciate the importance of controls providing effector function modulation and will include the LALAPG mutations as a standard component of our future ADCC evaluation. However, given our focus on the relevance of the epitope and consistency of the Fc regions across the antibodies, we felt that the isotype and positive control antibodies (target binding controls) were the most relevant controls to include in this study.</p><disp-quote content-type="editor-comment"><p>3) The chosen experimental conditions for HDXMS seemingly do not take into account the role of temperature on spike intrinsic ensemble heterogeneity (prefusion vs expanded) as previously described (PMID: 35236990). The authors must at least clarify why their HDXMS experimental conditions included thawing of frozen samples (-80 C) and brief (10 min) equilibration at 25 C instead of prolonged 37 C treatment. which favors the relevant prefusion conformation according to the above published study. Is the conformational heterogeneity in biological replicates equivalent following short incubation at 25 C and longer incubation at 37 C?</p></disp-quote><p>The HDX-MS experiments presented in this work were carried out by the D’Arcy lab and published in a preprint on bioRxiv (originally posted on February 1, 2021) prior to publication of Costello <italic>et al.</italic> (first posted to bioRxiv July 11, 2021, epub March 2, 2022). Indeed, our bioRxiv posting inspired the Marqusee lab to request 3A3 for inclusion in their work focused on the conformational heterogeneity of the spike protein. Without prior knowledge of the conformational heterogeneity, we carried out these epitope mapping experiments at 25 °C, which allowed us to successfully mapped the epitope without determining which conformation the antibody prefers.</p><p>The data presented in Costello <italic>et al.</italic> further confirms the location of 3A3’s epitope presented here and provides additional information about its preference for different conformational states within the spike protein. We have included an additional comment in the methods section stating, “The location of the 3A3 epitope was confirmed in a separate experiment carried out over the temperature range of 4 to 37 °C (Costello et al. 2022).”</p><p>This is a clear example of the value of pre-prints to stimulate timely scientific collaboration. While Costello <italic>et al.</italic> used 3A3 as a tool to probe spike dynamics, here we highlight the original work that identified the epitope.</p><disp-quote content-type="editor-comment"><p>4) The S2 hinge epitope is partially occluded by the S1 domain and access is contingent on RBD up-down conformational switching. The authors should better integrate findings from the various approaches described (HDX-MS, cryo-EM, antibody engineering) to help readers understand possible mechanisms for how antibodies bind this epitope.</p></disp-quote><p>Visualization of the 3A3/spike interaction by cryo-EM was not possible with full-length spike as the conformational heterogeneity of the S1 domains in the S2-open state was too great. For this reason, 3A3 Fab with the stabilized S2 domain of the spike were used to obtain cryo-EM images. In contrast, HDX-MS was performed with both 3A3 Fab and full-length 3A3 and full-length HexaPro spike. The accessibility of the epitope is quite different in these cases, likely resulting in different Fab occupancy depending on the presence of the S1 domains, making integration of the HDX-MS and cryo-EM results difficult.</p><p>Our main focus was to describe the location of this new class of S2 epitope, but because of the complexity of spike dynamics and the 3:2 ratio of binding sites, we lack sufficient evidence to make definitive claims about the exact mechanism of bivalent antibody binding.</p><p>We have added a new paragraph in the Discussion section to better lay out the complexity of the spike dynamics and how it may impact binding to the S2 hinge epitope:</p><p>“SARS-2 spike is a highly dynamic protein, sensitive to many variables including temperature (Edwards et al. 2021), pH (Zhou et al. 2020) and glycosylation (Casalino et al. 2020). Each of the RBDs have the potential to flip up, which has been captured in cryo-EM images of closed, one-up, two-up and three-up spikes (Benton et al. 2020). Additionally, molecular dynamics simulations indicated that movement of the S1 domains during opening extends deeper into the protein than previously appreciated (Zimmerman et al. 2021), while HDX analysis has observed an open-S2 conformation with a splayed spike trimer that exposes core S2 epitopes (Costello et al. 2022). Notably, these movements impact hinge epitope accessibility, indicating that antibody binding to this region involves multiple kinetic steps (Figure 2f). Data showing enhanced binding to spike variants favoring the S2 open state (Figure 2c-e) and similar neutralization of authentic spike on pseudo-viruses by 3A3 and RAY53 (Figure 5a) despite the latter’s increased affinity (Figure 4e) indicate that spike S2 opening is the rate-limiting step in antibody binding. Results shown here also underscore that these rates can vary depending on the local environment (soluble protein versus viral or infected cell surface) and amino acid changes present (stabilizing changes versus circulating variants), highlighting the importance of spike dynamics on antibody binding.”</p><disp-quote content-type="editor-comment"><p>5) A discussion of the allosteric effects of 3A3 binding to the spike trimer, particularly with regards to cooperativity in antibody binding is warranted. In this regard, the reader would also benefit from HDXMS spectral envelopes, at least for peptides within the epitope locus.</p></disp-quote><p>Thank you for this suggestion. Spectral envelopes have been provided (Supplementary Figure 4b and Supplementary Table 3).</p><p>The HDX-MS data provides limited insight into possible cooperative or allosteric binding of the 3A3 antibody because of other sources of heterogeneity such as spike dynamics and partial occupancy of the spike epitopes. However, no difference in occupancy was detected when HDX-MS with 3A3 Fab was compared to the same experiment with bivalent 3A3 IgG. It should be noted that in this HDX system, the antibody is not bound so tightly that the spectra are bimodal, showing the exchange of bound and unbound populations separately. Though HDX-MS experiments were performed in slight Fab or IgG excess of 1:1 Fab:spike monomer stoichiometry, the absolute stoichiometry in the context of the spike trimer is unclear.</p><disp-quote content-type="editor-comment"><p>6) In Figure 1A, regions lacking HDX-M/S coverage are indicated in grey, which is too similar to regions with coverage but with low/no rate of exchange. Please distinguish regions with and without coverage more clearly.</p></disp-quote><p>Thank you for this suggestion, this has been edited so that no coverage is black instead of grey in both Figure 1a and Supplementary Figure 4a.</p><disp-quote content-type="editor-comment"><p>7) In Figure 2F, please define dashed versus solid arrows.</p></disp-quote><p>Thank you, we have edited this image to include only solid arrows.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1) Readers would benefit from HDXMS spectral envelopes in figures, at least for the epitope locus peptides.</p><p>2) Authors should describe the ensemble heterogeneity observed in HDXMS and the basis for not applying a 37 deg C treatment of samples prior to HDXMS mapping studies with 3A3.</p><p>3) The reader would benefit from better integration of structural, solution (HDXMS), and antibody engineering approaches in the manuscript. This would bring out a more definitive conclusion on the mechanism of targeting the hinge epitope.</p><p>4) The authors should address the lack of allostery observed and cooperativity of antibody binding.</p></disp-quote><p>Please see the response to Essential Revisions #3, 4, and 5 discussing these points.</p></body></sub-article></article>